愛齊科技 (ALGN) 2019 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings. Welcome to the Align Technology Second Quarter 2019 Earnings Conference call. (Operator Instructions) Please note this conference is being recorded. I'll now turn the conference over to your host, Shirley Stacy, Vice President of Communications. Ms. Stacy, you may begin.

    各位好。歡迎參加 Align Technology 2019 年第二季財報電話會議。(接線員指示) 請注意,本次會議將被錄音。現在我將把會議交給今天的主持人——傳播副總裁 Shirley Stacy。Stacy 女士,您可以開始了。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Good afternoon, and thank you for joining us. Joining me today for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued second quarter 2019 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on August 7. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13691835, followed by #. International callers should dial (201) 612-7415 with the same conference number.

    各位下午好,感謝各位加入我們。今天與我一同出席電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們已於今日透過 GlobeNewswire 發布 2019 年第二季財務結果,並可於我們網站 investor.aligntech.com 查閱。今天的電話會議將以音訊網路直播,並將在我們網站上存檔約 12 個月。電話重播預計將於今日美東時間下午 5:30 左右提供,並持續至 8 月 7 日美東時間下午 5:30。美東時間。如需收聽電話重播,美國境內來電者請撥打 (877) 660-6853,會議號碼 13691835,然後按 #。國際來電者請撥打 (201) 612-7415,會議號碼相同。

  • As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events product outlook and the expected financial results for the third quarter of 2019. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the SEC. Actual results may vary significantly, and Align expresses -- expressly assumes no obligation to update four second quarter 2019 conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.

    提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2019 年第三季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會(SEC)提交的定期報告中更詳細說明。實際結果可能有重大差異,且 Align 明確表示不承擔更新義務;第二季 2019 年電話會議投影片已放在我們網站「季度結果」項下。請參閱這些檔案以取得更詳細資訊。

  • With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

    接下來,我將把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Shirley. Good afternoon, and thank you for joining us. On our call today, I'll provide some highlights for the second quarter, then briefly discuss the performance of our 2 operating segments, clear aligners and scanners. John will provide more detail on our financial results and discuss our outlook for the third quarter. Following that, I'll come back and summarize a few key points and open up the call to questions. Our second quarter revenues were at the high end of our guidance, reflecting Invisalign volume growth primarily from international doctors as well as very strong sales from iTero scanners and services.

    謝謝你,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將先提供第二季的一些重點,接著簡要說明我們兩個營運部門——隱形矯正器與掃描儀——的表現。John 將更詳細說明我們的財務結果,並討論第三季展望。之後我會再回來總結幾個關鍵重點,並開放提問。我們第二季營收位於財測區間的高端,主要反映 Invisalign 出貨量成長主要來自國際醫師,以及 iTero 掃描儀與服務非常強勁的銷售表現。

  • Q2 Invisalign volumes were 24.6% year-over-year compared to 30.5% year-over-year in second quarter 2018. It's reflecting continued adoption from teenage and younger patients as well as increased utilization and expansion of our customer base, which totaled over 60,000 active doctors worldwide. From a product perspective, we had good growth across Invisalign portfolio with noncomprehensive products outpacing comprehensive led by Invisalign Go globally. Total Invisalign case shipments for Q2 were lower than expected primarily due to softness in China related to a tougher consumer environment and slower growth in young adult cases in North America.

    第二季 Invisalign 出貨量年增 24.6%,相較於 2018 年第二季年增 30.5%。這反映青少年與更年輕患者的持續採用,以及客戶基礎的使用率提升與擴張;全球活躍醫師總數已超過 60,000 名。從產品角度來看,Invisalign 產品組合整體成長良好,其中非全口(noncomprehensive)產品的成長超越全口(comprehensive)產品,主要由全球 Invisalign Go 帶動。第二季 Invisalign 總病例出貨量低於預期,主要因中國在較嚴峻的消費環境下需求偏弱,以及北美年輕成人病例成長放緩。

  • Now let's turn to the specifics around our second quarter results, starting with the Americas region. The Americas region Q2 Invisalign case volumes was up 4.2% sequentially, 16.5% year-over-year compared to 22% year-over-year in Q2 2018, reflecting growth both in the orthodontist and GP channels as well as continued strength from teenage patients in Invisalign Go.

    現在我們來看第二季結果的細節,先從美洲地區開始。美洲地區第二季 Invisalign 病例量較前一季成長 4.2%,年增 16.5%,相較於 2018 年第二季年增 22%;這反映矯正專科與一般牙醫(GP)通路皆有成長,以及 Invisalign Go 在青少年患者方面持續強勁。

  • In Q2, we trained approximately 3,000 new Invisalign doctors in the Americas region, of which more than half were North American doctors. On a sequential basis, Q2 Invisalign volume growth reflects increased utilization for the Americas region overall. Driven by North American orthos at 18.9 cases per doc, with continued adoption of Invisalign with mandibular advancement and Invisalign First used to treat patients as young as 6 years old. We also had solid performance from GP dentist with continued momentum from Invisalign Lite and Invisalign Go. Invisalign Go is uniquely designed for GPs and features a digital chair-side experience using the iTero Intraoral Scanner and streamline tooth movement capabilities. It's a really great product, and we're very pleased with this performance, including with our DSO partners who are using it to help their providers introduce Invisalign treatment into practice. Invisalign Go integrates well with a DSO model, which remains a very important part of our overall business as we continue to see DSO growth rates outpacing the non-DSO doctors significantly.

    第二季我們在美洲地區培訓約 3,000 名新的 Invisalign 醫師,其中超過一半為北美醫師。以季比來看,第二季 Invisalign 量的成長反映美洲地區整體使用率提升。主要由北美矯正專科醫師帶動,每位醫師平均 18.9 例;同時 Invisalign 下顎前移(mandibular advancement)與 Invisalign First 的採用持續增加,後者可用於治療最小 6 歲的患者。一般牙醫(GP)也有穩健表現,Invisalign Lite 與 Invisalign Go 的動能持續。Invisalign Go 是專為一般牙醫設計的產品,具備使用 iTero 口內掃描儀的數位化診間端體驗,並提供簡化的牙齒移動能力。這是一個非常出色的產品,我們對其表現非常滿意;包括我們的 DSO 合作夥伴也在使用它,協助其醫療提供者將 Invisalign 治療導入診所。Invisalign Go 與 DSO 模式整合良好;DSO 仍是我們整體業務中非常重要的一部分,因為我們持續看到 DSO 的成長率顯著高於非 DSO 醫師。

  • Year-over-year, Q2 Invisalign volume growth in the Americas region was driven continued strength in the ortho channel with 19.7% growth compared to 25% year-over-year as well as increase of 11.6% from the GP channel. In Q2, we saw adult case growth for North American orthodontists reflecting a more crowded competitive environment, especially for young adults in the 20- to 29-year-old demographic who really value convenience and costs. We know there is about a 10% overlap with our adult demographic with SDC. Given increased awareness for the direct to consumer clear aligners and heavy advertising spend from DTC players, case starts may be shifting away from traditional practices. We also believe the doctors are sampling alternative products and are taking advantage of wires and bracket bundles that essentially gave clear aligners away for free or at very low prices. These competitive dynamics are not surprising and were validated during our recent customer visits. Nonetheless, they appear to be working themselves out in the first few weeks of Q3 and we've seen improving trends in North America.

    以年比來看,美洲地區第二季 Invisalign 量的成長主要由矯正專科通路的持續強勁所帶動,年增 19.7%(相較於年增 25%),以及一般牙醫通路年增 11.6%。第二季我們看到北美矯正專科醫師的成人病例成長,反映競爭環境更為擁擠,尤其是在 20 至 29 歲、重視便利性與成本的年輕成人族群。我們知道在成人族群中,與 SDC 約有 10% 的重疊。在直面消費者(DTC)隱形矯正器的認知度提升,以及 DTC 業者大量投放廣告支出的情況下,病例啟動可能正從傳統診所轉移。我們也認為醫師正在試用替代產品,並利用線材與托槽的組合方案,這些方案本質上等同於免費或以極低價格提供隱形矯正器。這些競爭動態並不令人意外,且在我們近期的客戶拜訪中得到驗證。儘管如此,這些情況似乎在第三季前幾週逐步消化,我們也看到北美趨勢正在改善。

  • In July, our executive team and I spent a week meeting with over 200 orthodontists in 4 major U.S. cities, Fort Lauderdale, Dallas, Denver and L.A., and did not hear anything that gave me pause about a competitive performance standpoint. That's not to say that we didn't get feedback about how to make things better, especially around to help doctors compete more effectively against DTC offerings, but doctors consistently told us that the Invisalign system is the best product there is hands down, technically and clinically. Given the changing DTC landscape, we're focused on further differentiation of Invisalign treatment for both consumers and doctors.

    7 月,我與我們的高階管理團隊花了一週時間,在美國 4 個主要城市——Fort Lauderdale、達拉斯、丹佛與洛杉磯——與超過 200 位矯正專科醫師會面,並未聽到任何讓我對競爭表現感到擔憂的訊息。這並不是說我們沒有收到如何做得更好的回饋,特別是如何協助醫師更有效地與 DTC 方案競爭;但醫師一再告訴我們,Invisalign 系統在技術與臨床上都是毫無疑問最好的產品。鑑於 DTC 版圖正在改變,我們正專注於進一步強化 Invisalign 治療對消費者與醫師的差異化。

  • In Q3, we're increasing investment in consumer demand with a new advertising campaign for North America and expanding marketing programs such as our concierge service, which connects potential patients with Invisalign doctors, increasing conversion and stickiness. In addition, we're launching new sales tools and professional marketing materials. We also expect to see increased productivity from the 100-plus sales representatives we added in Q1.

    第三季,我們將透過北美新的廣告活動加大對消費者需求的投資,並擴大行銷方案,例如我們的禮賓服務(concierge service),可將潛在患者與 Invisalign 醫師連結,提高轉換率與黏著度。此外,我們也將推出新的銷售工具與專業行銷素材。我們也預期第一季新增的 100 多位業務代表將帶來更高的生產力。

  • We'll also look for opportunities to leverage Invisalign product portfolio that doctors -- to treat patients as needed and compete with DTC offerings. Expanding on products like Invisalign Go and Lite will help close the gaps many doctors see with DTC patients who are looking for price and convenience. Finally, in Latin America, we continue to make great progress led by Brazil, in developing the emerging clear aligners segment in the world's leading market for beauty and cosmetic procedures. In Q2, Invisalign volume in Latin America was up significantly year-over-year, reflecting our ongoing investments as we continue to build our business in the region, training approximately 1,300 Invisalign doctors during the quarter.

    我們也將尋找機會,善用 Invisalign 產品組合,讓醫師能依需求治療患者,並與 DTC 方案競爭。擴展如 Invisalign Go 與 Lite 等產品,將有助於縮小許多醫師在面對追求價格與便利性的 DTC 患者時所看到的落差。最後,在拉丁美洲,我們在巴西的帶動下持續取得重大進展,致力於在全球美容與醫美程序領先的市場中,發展新興的隱形矯正器市場區隔。第二季拉丁美洲的 Invisalign 量年增顯著,反映我們持續投資並在該地區建立業務;本季我們培訓約 1,300 名 Invisalign 醫師。

  • For our international business, Q2 was a good quarter with strong Invisalign volume growth of 36.7% year-over-year, reflecting increased Invisalign utilization and continued expansion of our customer base in both EMEA and the Asia Pacific region. On a sequential basis, international volume was up nicely, reflecting growth in both the EMEA and Asia Pacific regions. In Q2, we trained approximately 3,500 new Invisalign doctors internationally, over half of which were in the Asia Pacific region.

    就我們的國際業務而言,第二季表現良好,Invisalign 出貨量年增 36.7%,反映 Invisalign 使用率提升,以及我們在 EMEA 與亞太地區客戶基礎持續擴張。以季比來看,國際出貨量亦有不錯的成長,反映 EMEA 與亞太地區皆呈現增長。第二季我們在國際市場培訓約 3,500 位新的 Invisalign 醫師,其中超過一半位於亞太地區。

  • In EMEA, Q2 was another strong quarter with volumes up 39% year-over-year, driven by growth across the region, with record Invisalign volumes in all but 1 country market led by Iberia. We saw strength across the Invisalign product portfolio with continued momentum from Invisalign Go. We also continue to see strong growth across our key expansion markets as well led by Central and Eastern Europe.

    在 EMEA,第二季再度是強勁的一季,出貨量年增 39%,成長動能來自整個區域;除 1 個國家市場外,其餘各國皆創下 Invisalign 出貨量新高,其中以伊比利亞半島領先。我們看到 Invisalign 產品組合全面走強,Invisalign Go 的動能持續。我們也持續看到關鍵擴張市場的強勁成長,其中以中東歐地區領先。

  • For APAC, Q2 Invisalign volume increased 33.1% year-over-year, reflecting continued growth from nearly all country markets led by China, Japan and ANZ. We also had strong growth from GP dentists, which were up 52.4% year-over-year. On a sequential basis, Q2 Invisalign volume for APAC was up nicely led by Japan, Southeast Asia, Hong Kong and Taiwan. We also had an uptick in adult patients in Q2 following a very strong quarter for teen cases in Q1 in conjunction with a teenage promotion to help drive trial and adoption in the very important teen segment.

    就亞太(APAC)而言,第二季 Invisalign 出貨量年增 33.1%,反映幾乎所有國家市場持續成長,其中以中國、日本與澳紐(ANZ)領先。我們也看到一般牙醫(GP)帶來的強勁成長,年增 52.4%。以季比來看,亞太第二季 Invisalign 出貨量亦有不錯的成長,主要由日本、東南亞、香港與台灣帶動。在第一季青少年病例非常強勁、並配合青少年促銷以推動試用與採用(青少年是非常重要的族群)之後,第二季成人患者也出現回升。

  • During Q2, we trained over 1,900 new doctors in APAC. Over 40% were in China. Notwithstanding current consumer sentiment, we remain confident in the long-term opportunity in China. We continue to invest in our manufacturing operations and training centers to ensure that we operate like a local company and have the capabilities to expand and scale our business as the environment improves. We're also focusing on what we can influence directly to help mitigate consumer sentiment in China. We're expanding our reach and scope in Tier 3 and Tier 4 cities across China, including investment in a GP dentist sales force and sales programs centered on Invisalign Go. In the last year, since the launch of Invisalign Go in APAC, we have learned that doctors benefit from a differentiated approach in training and support, and we'll align our resources accordingly.

    第二季期間,我們在亞太培訓超過 1,900 位新醫師。其中超過 40% 位於中國。儘管目前消費者情緒影響,我們仍對中國的長期機會充滿信心。我們持續投資製造營運與培訓中心,以確保我們能像在地公司一樣運作,並具備在環境改善時擴張與規模化業務的能力。我們也聚焦於我們能直接影響的事項,以協助緩解中國的消費者情緒影響。我們正擴大在中國三、四線城市的觸及範圍與覆蓋面,包括投資一般牙醫(GP)銷售團隊,以及以 Invisalign Go 為核心的銷售方案。過去一年,自 Invisalign Go 在亞太推出以來,我們了解到醫師在培訓與支援方面受益於差異化的方法,我們將據此調整資源配置。

  • We're also increasing consumer marketing spend in APAC, including new advertising like our doctor-centered ad that is launching in North America next week. Finally, in the second half of this year, we expect to have dozens of Invisalign pop-up centers in China to ensure we educate consumers and connect more with Invisalign doctors.

    我們也在亞太提高消費者行銷支出,包括新的廣告,例如以醫師為核心的廣告,將於下週在北美推出。最後,在今年下半年,我們預期在中國設立數十個 Invisalign 快閃中心,以確保我們能教育消費者,並與更多 Invisalign 醫師建立連結。

  • Outside of China, we have strong growth across APAC, including Japan, ANZ, Hong Kong, Taiwan. We will continue to drive adoption and utilization by investing through sales and marketing programs and clinical education with new training centers like the one we just announced in Taiwan. Through this center, we have also launched the first integrated postgraduate Invisalign training program in Asia with National Taiwan University Hospital. Clinical education and peer-to-peer learning is one of the most impactful ways we help drive adoption of Invisalign treatment. During Q2, we engaged directly with thousands of Invisalign-trained doctors around the world, providing them with the ability to learn from clinical experts and practice development leaders and share their experience and insights with each other.

    在中國以外,我們在亞太各地仍有強勁成長,包括日本、澳紐(ANZ)、香港與台灣。我們將持續透過銷售與行銷方案以及臨床教育投資,推動採用與使用率提升,例如我們剛在台灣宣布的新培訓中心。透過該中心,我們也與國立臺灣大學醫院共同推出亞洲首個整合式 Invisalign 研究所後培訓計畫。臨床教育與同儕學習是我們推動 Invisalign 治療採用最具影響力的方法之一。第二季期間,我們在全球直接與數千位受過 Invisalign 培訓的醫師互動,讓他們能向臨床專家與診所經營發展領域的領導者學習,並彼此分享經驗與洞見。

  • In April, we held a 2019 Invisalign China forum in Xi'an, attracting 1,300 industry practitioners and gathering together over 40 experienced orthodontists from all over the country. During the 2-day forum, participants held in-depth discussions on frontier topics, such as adolescent orthodontics, extraction and orthodontic treatment and digital dentistry.

    4 月,我們在西安舉辦 2019 Invisalign 中國論壇,吸引 1,300 位業界從業者,並匯聚全國超過 40 位資深矯正醫師。在為期 2 天的論壇中,與會者就青少年矯正、拔牙與矯正治療、數位牙科等前沿議題進行深入討論。

  • In May, 300 high-volume dentists from 37 countries across the Americas, EMEA and APAC participated in an inaugural addition of the Invisalign Symposium on Digital Practice in London. The 2-day doctor event featured specially designed sessions combining plenary interaction, small group of working sessions covering such topics as understanding consumers, practice optimization, challenges of building a digital practice, among others. I was able to address specifically on the digital practice and driving the evolution of digital orthodontics with supporting talks on digital transformation and health care and the power of digital treatment planning along with the practice optimization with ADAPT.

    5 月,來自美洲、EMEA 與亞太 37 個國家的 300 位高出貨量牙醫,參加了在倫敦舉辦的首屆「Invisalign 數位診所實務研討會」(Invisalign Symposium on Digital Practice)。這場為期 2 天的醫師活動包含特別設計的議程,結合全體會議互動與小組工作坊,涵蓋理解消費者、診所最佳化、建立數位化診所的挑戰等主題。我也就數位診所與推動數位矯正演進進行專題分享,並以數位轉型與醫療照護、數位治療規劃的力量,以及結合 ADAPT 的診所最佳化等內容作為支持性演講。

  • ADAPT is Align's consultative program to provide practices with personalized support to help doctors and staff navigate the journey from a braces model to an aligner model in a timely, efficient and profitable manner. Emphasis is on digital workflow, finances and consumer acquisition and early results from test sites in the Americas, EMA and APAC show significant improvements in conversion, revenue growth, practice profits and other key metrics as practices shift to a digital model and increase their Invisalign share of chair.

    ADAPT 是 Align 的顧問式計畫,為診所提供個人化支援,協助醫師與員工以即時、高效率且具獲利性的方式,從傳統牙套模式轉型為隱形矯正器模式。重點在於數位工作流程、財務與消費者獲取;而來自美洲、EMEA 與亞太測試據點的初步結果顯示,隨著診所轉向數位模式並提高其 Invisalign 椅旁占比(share of chair),在轉換率、營收成長、診所獲利與其他關鍵指標方面皆有顯著改善。

  • In June, we hosted the first Invisalign Scientific Symposium in EMEA located in Valencia, Spain. The Scientific Symposium focused on evidence-based success cases for Invisalign treatment in growing patients with dedicated focus on treatments with Invisalign First and mandibular advancement feature, bringing together nearly 200 of EMEA's most experienced Invisalign doctors. In July, more than 175 general dentists from all across Europe attended the second annual Invisalign GP Growth Summit in Berlin, focused on peer-to-peer learning and emerging industry trends.

    6 月,我們在西班牙瓦倫西亞舉辦 EMEA 首屆 Invisalign 科學研討會(Invisalign Scientific Symposium)。該科學研討會聚焦於成長期患者 Invisalign 治療的實證成功案例,並特別著重 Invisalign First 與下顎前移功能(mandibular advancement feature)相關治療,匯聚近 200 位 EMEA 最資深的 Invisalign 醫師。7 月,來自歐洲各地超過 175 位一般牙醫參加了在柏林舉辦的第二屆年度 Invisalign GP Growth Summit,重點聚焦同儕學習與新興產業趨勢。

  • We also just hosted our first Invisalign Teen Summit with about 300 doctors and staff in Los Angeles. The Summit program was focused completely on teen treatment and teen culture and included a tie-in with VidCon, the top teen culture and community event where Align held a multiyear relationship and strong brand presence. Teen Summit is designed to turn low teen submitters into high teen submitters by combining Invisalign specific clinical and practice how-tos with an immersive teen culture experience, social media support and training and insights from teen influencers.

    我們也剛在洛杉磯舉辦首屆 Invisalign Teen Summit,約有 300 位醫師與員工參與。峰會議程完全聚焦於青少年治療與青少年文化,並與 VidCon 連動;VidCon 是頂尖的青少年文化與社群活動,Align 與其建立多年合作關係並擁有強勢品牌能見度。Teen Summit 的設計目標,是透過結合 Invisalign 專屬的臨床與診所實務操作、沉浸式青少年文化體驗、社群媒體支援與訓練,以及青少年意見領袖的洞見,將低青少年提交量的醫師轉變為高青少年提交量的醫師。

  • Speaking of teens, in Q2, over 100,000 teenagers started treatment with Invisalign clear aligners, an increase of 32.2% year-over-year, driven by continued strong adoption across all major regions. For Q2, year-over-year Invisalign teen patient growth for North America orthodontists increased 25% and international doctors were up 44.4%. Invisalign First and Invisalign treatment with mandibular advancement continued to ramp globally and are helping to increase our share of teenagers and younger patients worldwide. Overall, we're very pleased to see the use of Invisalign treatment among teenagers continues to outpace adults and that Invisalign First is driving really strong growth in the kid/tween segment. In fact, we reached our 7 millionth Invisalign patient during the quarter, a child in the United States being treated with Invisalign First. Since the launch of Invisalign First a year ago, kids under 10 years old have become our fastest-growing demographic, up 140% year-over-year, which also bodes well for the continued adoption of teens too.

    談到青少年,第二季有超過 100,000 名青少年開始使用 Invisalign 隱形牙套進行治療,年增 32.2%,主要由各大區域持續強勁的採用所帶動。就第二季而言,北美矯正醫師的 Invisalign 青少年患者年增 25%,國際醫師則年增 44.4%。Invisalign First 與具下顎前移功能的 Invisalign 治療在全球持續加速推進,並有助於提升我們在全球青少年與更年幼患者中的市占。整體而言,我們很高興看到青少年使用 Invisalign 治療的成長持續超越成人,而 Invisalign First 正在兒童/青少年前期(kid/tween)族群帶動非常強勁的成長。事實上,本季我們達成第 700 萬名 Invisalign 患者里程碑,該患者是美國一名接受 Invisalign First 治療的兒童。自 Invisalign First 於一年前推出以來,10 歲以下兒童已成為我們成長最快的族群,年增 140%,這也為青少年族群的持續採用帶來正面訊號。

  • Our consumer marketing efforts are designed to build the category and drive demand for Invisalign treatment through a doctor's office. We invest over $120 million each year in consumer marketing programs, including TV, digital and social media, PR, event marketing and our patient concierge service. Our goals are to make the Invisalign brand a household name worldwide and to motivate consumers to seek Invisalign treatment through a doctor's office.

    我們的消費者行銷工作旨在建立品類並透過醫師診所推動對 Invisalign 療程的需求。我們每年在消費者行銷計畫上投資超過 1.2 億美元,包括電視、數位與社群媒體、公關、活動行銷以及我們的病患禮賓服務。我們的目標是讓 Invisalign 品牌在全球成為家喻戶曉的名稱,並促使消費者透過醫師診所尋求 Invisalign 療程。

  • In Q2, we continue to see strong digital engagement with the consumers, reaching nearly 4.3 million unique visitors on invisalign.com sites worldwide for a total of 57.5 million visitors to date. Our other key metrics show increased activity engagement with the Invisalign brand and are included in our Q2 quarterly slides.

    在第二季,我們持續看到與消費者之間強勁的數位互動,全球 invisalign.com 網站觸及近 430 萬名不重複訪客,累計至今總訪客數達 5,750 萬。我們其他關鍵指標亦顯示與 Invisalign 品牌相關的互動活動增加,並已納入我們第二季季度簡報投影片中。

  • During the quarter, we developed a new consumer advertising campaign for 3 largest markets, the U.S., Canada and China. This new multichannel campaign, which launches across North America this Monday, educates consumers on the significant benefits of Invisalign treatment, highlighting our patented SmartTrack technology based on years of research, which moves teeth more predictably and comfortably, combined with the personalized care of a doctor. We are more than doubling our media investment behind this new multichannel campaign to extend our reach across adults and parents of teens, increasing our reach frequency from 50% to over 70% in order to capture even more of our targeted audiences.

    本季期間,我們為三大市場——美國、加拿大與中國——開發了新的消費者廣告活動。這項新的多通路活動將於本週一在北美全面啟動,向消費者說明 Invisalign 療程的重大效益,並強調我們基於多年研究的專利 SmartTrack 技術,可更可預測且更舒適地移動牙齒,並結合醫師的個人化照護。我們將在這項新多通路活動上的媒體投資提高至兩倍以上,以擴大對成人與青少年家長的觸及,將觸及頻率由 50% 提升至超過 70%,以捕捉更多目標受眾。

  • In the U.S., our new campaign will run across all media channels, including broadcast in TV networks; connected TV, such as Hulu and other streaming services; digital media; and all social media channels.

    在美國,我們的新活動將涵蓋所有媒體通路,包括電視聯播網的傳統播出;連網電視(如 Hulu 及其他串流服務);數位媒體;以及所有社群媒體通路。

  • In Canada, our new app will go live on digital channels first, and then we will layer in TV in the coming weeks. And China will follow suit in the second half.

    在加拿大,我們的新應用將先於數位通路上線,接著在未來幾週再加入電視投放。而中國將於下半年跟進。

  • Q2 was another outstanding quarter for our iTero scanner and services business, with revenues up 82.4% year-over-year, reflecting continued strength across all regions and customer channels, including large account DSOs.

    第二季對我們的 iTero 掃描儀與服務業務而言是另一個表現卓越的季度,營收年增 82.4%,反映所有地區與客戶通路(包括大型帳戶 DSO)持續強勁。

  • On a sequential basis, revenues were up 30.4% sequentially, reflecting higher scanner sales following a seasonally weaker Q1, especially in North America and Asia Pacific. Industry Services revenues reflect higher subscriptions from installed base growth and multiyear deals.

    以季比來看,營收季增 30.4%,反映在第一季季節性較弱之後掃描儀銷售增加,尤其是在北美與亞太地區。產業服務營收則反映因裝機基礎成長與多年期合約帶來的更高訂閱收入。

  • During the quarter, we saw continued adoption of the iTero Element 5D imaging system in EMEA, APAC and Canada since its commercial launch at IDS in the first quarter of the year. Cumulatively, over 13.7 million orthodontic scans and 3.6 million restorative scans have started with iTero scanners. Use of the iTero scanners for Invisalign case submission continues to grow and remains a positive catalyst for Invisalign utilization.

    本季期間,自今年第一季於 IDS 商業上市以來,我們看到 iTero Element 5D 影像系統在 EMEA、APAC 與加拿大持續被採用。累計而言,已有超過 1,370 萬次矯正掃描與 360 萬次修復掃描由 iTero 掃描儀啟動。使用 iTero 掃描儀提交 Invisalign 病例的比例持續成長,並仍是推動 Invisalign 使用量的正向催化因素。

  • For Q2, total Invisalign cases submitted with digital scanner in the Americas increased to 77.3% from 69.6% in Q2 last year. International scans increased 60.8%, up from 47.8% the same quarter last year. Within the Americas, 92.3% of cases submitted by North American orthos were submitted digitally.

    在第二季,美洲地區以數位掃描儀提交的 Invisalign 病例占比提升至 77.3%,高於去年第二季的 69.6%。國際市場的數位掃描占比提升至 60.8%,高於去年同季的 47.8%。在美洲地區內,北美矯正醫師提交的病例中有 92.3% 為數位提交。

  • We continue to expand the iTero portfolio to address doctors' needs and enable them to more easily adopt Invisalign treatment in their practices. In June, we announced the iTero Element Foundation, extending the portfolio to offer dentists digital workflow capabilities to address their restorative and patient monitoring and intraoral scaring needs. The streamlined workflows to dental laboratories includes an option for on-demand chair-side milling, an exclusive time-lapse technology for patient communication and monitoring with the iTero Element Foundation, which provides dentists with capabilities beyond basic STL support scanners. Software upgrade pathways are also available for Invisalign clear aligners.

    我們持續擴充 iTero 產品組合,以滿足醫師需求並讓他們在診所中更容易採用 Invisalign 療程。6 月,我們宣布推出 iTero Element Foundation,擴展產品組合,為牙醫提供數位工作流程能力,以滿足其修復、病患監測以及口內掃描需求。面向牙科技工所的精簡工作流程包含按需診間(chair-side)即時研磨的選項,以及 iTero Element Foundation 所提供、用於病患溝通與監測的獨家縮時(time-lapse)技術,讓牙醫具備超越僅支援基本 STL 的掃描儀之能力。同時也提供 Invisalign 隱形矯正器的軟體升級路徑。

  • The iTero scanner and services business has become an integral part of our business and is key to our end-to-end digital workflow. We believe that every exam should begin with an iTero digital scan because it's a better experience. It improves treatment outcomes and it provides doctor with a chair-side tool that enables patients to visualize their full -- their future smiles at chair-side in less than a minute without any goop, which increases treatment acceptance and drive practice growth.

    iTero 掃描儀與服務業務已成為我們業務不可或缺的一部分,並且是我們端到端數位工作流程的關鍵。我們相信每一次檢查都應以 iTero 數位掃描開始,因為這是更好的體驗。它能改善治療結果,並為醫師提供診間工具,使病患在不到一分鐘內、無需任何印模膠材,即可在診間視覺化他們未來的笑容,進而提高治療接受度並帶動診所成長。

  • Before I turn the call over to John, I want to mention the decision to terminate discussions regarding a possible development and distribution agreement that was disclosed as part of the patent settlement agreement with Straumann. As part of this settlement, Align and Straumann signed a nonbinding letter of intent to assess the possibility of a 5-year global development and distribution agreement whereby Straumann would distribute 5,000 iTero Element scanners. Additionally, we considered exploring the possibility of offering existing iTero users access to Straumann's prosthetic and surgical planning workflows.

    在我把電話會議交給 John 之前,我想提及我們決定終止就可能的開發與經銷協議所進行的討論;該事項先前已作為與 Straumann 的專利和解協議的一部分而揭露。作為該和解的一部分,Align 與 Straumann 簽署了一份不具約束力的意向書,以評估一項為期 5 年的全球開發與經銷協議之可能性,依該協議 Straumann 將經銷 5,000 台 iTero Element 掃描儀。此外,我們也考慮探索讓既有 iTero 使用者可使用 Straumann 的假體與手術規劃工作流程之可能性。

  • In June, after months of deliberation, we announced a decision to terminate these discussions, and as a result, we received an additional $16 million from Straumann for a total of $51 million settlement.

    6 月,經過數月審慎評估後,我們宣布決定終止上述討論,因此我們自 Straumann 額外收到 1,600 萬美元,使和解金總額達 5,100 萬美元。

  • With that, I'll now turn the call over to John.

    接下來,我將把電話會議交給 John。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Thanks, Joe. Now for our Q2 financial results. Total revenue for the second quarter was $600.7 million, up 9.4% from the prior quarter and up 22.5% from the corresponding quarter a year ago. Year-over-year revenue growth includes approximately $19 million or 4 points of unfavorable foreign exchange. For clear aligners, Q2 revenue of $496.7 million was flat sequentially due to Invisalign volume growth in most geographies, partially offset by lower Invisalign ASPs and lower SDC volume. Year-over-year clear aligner revenue growth of 14.6% reflects strong Invisalign shipment growth across all customer channels and geographies, partially offset by lower ASPs.

    謝謝,Joe。接著說明我們第二季的財務結果。第二季總營收為 6.007 億美元,較前一季成長 9.4%,較去年同期成長 22.5%。年增營收成長包含約 1,900 萬美元(或 4 個百分點)的不利匯率影響。就隱形矯正器而言,第二季營收為 4.967 億美元,季比持平,原因是多數地區 Invisalign 量成長,部分被較低的 Invisalign 平均銷售單價(ASP)以及較低的 SDC 量所抵銷。隱形矯正器營收年增 14.6%,反映所有客戶通路與各地區 Invisalign 出貨量強勁成長,部分被較低的 ASP 所抵銷。

  • On June 1, we had a minor issue with a standard software release that impacted some ClinCheck modifications. It was addressed and communicated to customers quickly. However, it required some Invisalign doctors to rereview their treatment plans. This disrupted the workflow for many doctors, which was compounded by an increase in call volumes to our treat operations and customer care center that degraded service levels and customer experience. While it's impossible to quantify, on the margin, it probably didn't help the quarter.

    6 月 1 日,我們在一次標準軟體版本釋出中出現一個小問題,影響了部分 ClinCheck 修改。我們很快就處理並向客戶溝通。然而,這仍需要部分 Invisalign 醫師重新審閱其治療計畫。這使許多醫師的工作流程受到干擾;同時,打到我們治療營運與客戶服務中心的來電量增加,進一步拉低服務水準與客戶體驗。雖然難以量化,但就邊際而言,這可能對本季表現沒有幫助。

  • Q2 Invisalign ASPs were down sequentially by approximately $15 to $1,230 primarily due to unfavorable foreign exchange and discounts. On a year-over-year basis, Q2 Invisalign ASPs were down $85 primarily reflecting promotional discounts, unfavorable foreign exchange, higher deferrals related to additional aligners and product mix shift, partially offset by price increases.

    第二季 Invisalign ASP 季比下降約 15 美元至 1,230 美元,主要由不利匯率與折扣所致。以年比來看,第二季 Invisalign ASP 下降 85 美元,主要反映促銷折扣、不利匯率、與追加矯正器相關的較高遞延以及產品組合轉移,部分被漲價所抵銷。

  • Total Q2 Invisalign shipments of 377,100 cases were up 8% sequentially and up 24.6% year-over-year. For Americas orthodontists, Q2 Invisalign case volume was up 3.7% sequentially and up 19.7% year-over-year. For Americas GP dentists, Invisalign case volume was up 4.9% sequentially and up 11.6% year-over-year. For international doctors, Invisalign case volume was up 13.4% sequentially and up 36.7% year-over-year. Our scanner and services revenue for the second quarter was $104 million, up 30.4% sequentially, reflecting growth across all regions and channels, including DSOs, partially offset by lower ASP. Year-over-year revenue was up 82.4% primarily due to higher scanner units across regions and related services revenues, partially offset by lower ASP.

    第二季 Invisalign 總出貨量為 377,100 例,季增 8%,年增 24.6%。就美洲矯正醫師而言,第二季 Invisalign 病例量季增 3.7%,年增 19.7%。就美洲一般牙醫(GP)而言,Invisalign 病例量季增 4.9%,年增 11.6%。就國際醫師而言,Invisalign 病例量季增 13.4%,年增 36.7%。我們第二季掃描儀與服務營收為 1.04 億美元,季增 30.4%,反映所有地區與通路(包括 DSO)成長,部分被較低 ASP 所抵銷。年比營收成長 82.4%,主要由各地區掃描儀出貨台數增加及相關服務營收帶動,部分被較低 ASP 所抵銷。

  • Moving on to gross margin, Second quarter overall gross margin was 72%, down 1.2 points sequentially and down 2.6 points year-over-year. Gross margin was impacted by approximately 1 point year-over-year due to unfavorable foreign exchange. Clear aligner gross margin for the second quarter was 73.7%, down 1.2 points sequentially primarily due to cost from seasonally higher doctor training and freight. Clear aligner gross margin was down 2.8 points year-over-year primarily due to increased aligners per case and lower ASPs, as just described. Scanner gross margin for the second quarter was 63.6%, flat sequentially and up 4 points year-over-year primarily due to increased manufacturing efficiencies, partially offset by lower ASP, driven by mix.

    接著談毛利率,第二季整體毛利率為72%,較前一季下降1.2個百分點,較去年同期下降2.6個百分點。由於不利的外匯因素,毛利率較去年同期約受到1個百分點的影響。第二季透明牙套(Clear aligner)毛利率為73.7%,較前一季下降1.2個百分點,主要因季節性較高的醫師培訓與運費成本所致。透明牙套毛利率較去年同期下降2.8個百分點,主要因每病例牙套數增加及平均售價(ASP)降低,如前所述。第二季掃描儀毛利率為63.6%,較前一季持平,較去年同期上升4個百分點,主要因製造效率提升,部分被因產品組合驅動的ASP下降所抵銷。

  • Q2 operating expenses were $255.8 million, down sequentially 18.6% and up 5.3% year-over-year. The sequential decrease in operating expenses reflects a benefit of $51 million related to the Straumann litigation settlement, partially offset by our continued investment in sales and R&D activities. Additionally, Q1 operating expenses included $29.8 million related to Invisalign store closure costs. On a year-over-year basis, operating expense increased due to sales and R&D activities and was partially offset by the Straumann settlement.

    第二季營業費用為2.558億美元,較前一季下降18.6%,較去年同期上升5.3%。營業費用的季比下降反映了與Straumann訴訟和解相關的5,100萬美元利益,部分被我們持續投資於銷售與研發活動所抵銷。此外,第一季營業費用包含與Invisalign門市關閉成本相關的2,980萬美元。以年比來看,營業費用因銷售與研發活動而增加,並部分被Straumann和解所抵銷。

  • Second quarter operating expense included a $51 million benefit from the Straumann litigation settlement, which increased Q2 operating margin by approximately 8 points and diluted earnings per share by $0.57, respectively. This settlement was higher than anticipated in our Q2 guidance because it included an additional $16 million benefit from the termination of development and distribution agreement, along with $5 million that would've been incurred for development.

    第二季營業費用包含來自Straumann訴訟和解的5,100萬美元利益,分別使第二季營業利益率提高約8個百分點,並使每股盈餘稀釋0.57美元。該和解金額高於我們在第二季指引中的預期,因其包含終止開發與經銷協議所帶來的額外1,600萬美元利益,以及原本將發生的500萬美元開發費用。

  • Our second quarter operating income was $176.5 million, up 101.2% sequentially and up 43.8% year-over-year. Our second quarter operating margin was 29.4%, up 13.4 points sequentially and up 4.4 points year-over-year. The sequential increases in both operating income and operating margin are primarily attributed to the $51 million benefit related to the Straumann settlement recorded in the second quarter and the Invisalign store closure costs recorded in Q1 2019. On a year-over-year basis, the increases in operating income and operating margin primarily reflect the benefit from the Straumann settlement, partially offset by lower gross margin and continued investments in sales and R&D.

    第二季營業利益為1.765億美元,較前一季上升101.2%,較去年同期上升43.8%。第二季營業利益率為29.4%,較前一季上升13.4個百分點,較去年同期上升4.4個百分點。營業利益與營業利益率的季比上升,主要歸因於第二季認列與Straumann和解相關的5,100萬美元利益,以及2019年第一季認列的Invisalign門市關閉成本。以年比來看,營業利益與營業利益率的增加主要反映Straumann和解帶來的利益,部分被較低的毛利率及持續在銷售與研發上的投資所抵銷。

  • Interest, other income and expense of $17.4 million includes the $15.8 million gain that is related to our sale of equity investment in SmileDirectClub during the second quarter. With regards to second quarter tax provision, our tax rate was 22.2%, which includes approximately $10 million of tax expense related to gains from the Straumann settlement and the sale of the SDC equity investment. Second quarter diluted earnings per share was $1.83, up $0.94 sequentially and up $0.53 compared to the prior year.

    利息及其他收入與費用為1,740萬美元,其中包含與我們於第二季出售SmileDirectClub股權投資相關的1,580萬美元收益。就第二季所得稅提列而言,我們的稅率為22.2%,其中包含約1,000萬美元的稅費,與Straumann和解及出售SDC股權投資的收益相關。第二季稀釋後每股盈餘為1.83美元,較前一季增加0.94美元,較去年同期增加0.53美元。

  • Moving on to the balance sheet. As of June 30, 2019, cash, cash equivalents and marketable securities, including both short and long-term investments, were $765.9 million, an increase of $33.4 million from the prior quarter, which is primarily due to higher cash flow from operations, partially offset by $49.5 million used to repurchase approximately 161,000 shares of our stock. Of our $765.9 million of cash, cash equivalents and marketable securities, $582.4 million was held in the U.S. and $183.5 million was held by our international entities.

    接著看資產負債表。截至2019年6月30日,現金、約當現金及有價證券(包含短期與長期投資)為7.659億美元,較前一季增加3,340萬美元,主要因營運現金流增加,部分被用於回購約161,000股股票的4,950萬美元所抵銷。在7.659億美元的現金、約當現金及有價證券中,5.824億美元持有於美國,1.835億美元由我們的海外實體持有。

  • Q2 accounts receivable balance was $520.1 million, up approximately 8.5% sequentially. Our overall days sales outstanding, DSO was 77 days, down 1 day sequentially and up 9 days from Q2 last year. Cash flow from operations for the second quarter was $177.4 million, up $37.6 million compared to the prior year. Capital expenditures for the second quarter were $45.3 million primarily related to our continued investment in increasing aligner capacity and facilities. Free cash flow for the second quarter, defined as cash flow from operations, less capital expenditures, amounted to $132 million.

    第二季應收帳款餘額為5.201億美元,較前一季約增加8.5%。整體應收帳款週轉天數(DSO)為77天,較前一季減少1天,較去年第二季增加9天。第二季營運活動現金流為1.774億美元,較去年同期增加3,760萬美元。第二季資本支出為4,530萬美元,主要與我們持續投資以提升牙套產能與設施相關。第二季自由現金流(定義為營運活動現金流減資本支出)為1.32億美元。

  • During Q2 2019, we purchased on the open market approximately 161,000 shares of our common stock at an average price of $307.48 per share, including commission, for an aggregate purchase price of $49.5 million. We have $400.5 million remaining available for our repurchase under the May 2018 Repurchase Program.

    2019年第二季期間,我們在公開市場以每股平均307.48美元(含手續費)買回約161,000股普通股,合計買回金額為4,950萬美元。在2018年5月回購計畫下,我們尚有4.005億美元可用於回購。

  • With that, let's turn to our Q2 -- Q3 outlook and the factors that have formed our view, starting with the demand outlook. As we exited Q2 and now into the first weeks of Q3, we are seeing improving volume trends. For international, we expect Q3 volumes to be down sequentially, reflecting a seasonality slower period for EMEA, partially offset by seasonally stronger period for the APAC regions. However, given the uncertainty in China, we are reflecting a more cautious outlook for APAC growth. For the Americas, we expect Q3 volumes to be up sequentially, reflecting growth across all key country markets as well as a seasonally stronger period for North America.

    接下來我們來看第二季到第三季的展望,以及形成我們觀點的因素,先從需求展望開始。在第二季結束並進入第三季的前幾週,我們看到量的趨勢正在改善。就國際市場而言,我們預期第三季出貨量將較前一季下降,反映EMEA進入季節性較淡的期間,部分被APAC地區季節性較旺的期間所抵銷。然而,鑑於中國的不確定性,我們對APAC成長採取更為審慎的展望。就美洲市場而言,我們預期第三季出貨量將較前一季上升,反映所有主要國家市場的成長,以及北美進入季節性較旺的期間。

  • (technical difficulty)

    (技術困難)

  • orthodontists as with the peak of the summer teen season along with increased media spend and the launch of our new customer advertising campaign, as Joe described earlier. As we typically see, we expect overall Invisalign volume to be flat to slightly up from Q2. We expect our iTero business to be down sequentially coming off of another very strong quarter and record growth in Q2. Year-over-year, the iTero business continues to grow across all regions. And regarding SmileDirectClub, we expect no clear aligner volume from SDC in Q3.

    矯正醫師端亦然,隨著暑期青少年旺季達到高峰,加上媒體投放增加以及我們推出新的客戶廣告活動,如Joe先前所述。如同我們通常看到的情況,我們預期整體Invisalign出貨量將與第二季持平至小幅上升。我們預期iTero業務在經歷另一個非常強勁的季度以及第二季創紀錄的成長後,第三季將較前一季下降。以年比來看,iTero業務在所有地區持續成長。至於SmileDirectClub,我們預期第三季不會有來自SDC的透明牙套出貨量。

  • With this as a backdrop, we expect the third quarter to shape up as follows: Invisalign case volume is expected to be in the range of 370,000 to 380,000 cases, up approximately 16% to 19% year-over-year on a tough comp from Q3 last year, which had record shipments that benefited from the teen and adult promotions by approximate 2% higher growth rate; we expect Q3 revenue to be in the range of $585 million to $600 million, up approximately 16% to 19% year-over-year. Our Q3 revenue outlook assumes no SmileDirectClub volume compared to the same quarter a year ago where aligners supplied to SDC contributed about $8 million to revenue. In addition, as just mentioned, in Q3 2018, we had higher Invisalign volumes due to promotions, but lower ASPs.

    在此背景下,我們預期第三季表現如下:Invisalign病例量預計介於370,000至380,000例,較去年同期約成長16%至19%;去年第三季的比較基期較具挑戰,當時出貨創新高,受青少年與成人促銷帶動,成長率約高出2%;我們預期第三季營收介於5.85億至6.00億美元,較去年同期約成長16%至19%。我們的第三季營收展望假設不包含任何SmileDirectClub出貨量;相較之下,一年前同季供應給SDC的牙套約貢獻800萬美元營收。此外,如前所述,2018年第三季因促銷使Invisalign出貨量較高,但ASP較低。

  • We expect Q3 gross margin to be in the range of 71.9% to 72.5%. Q3 gross margin is up slightly compared to Q2 as we expect improvement due to price increases and manufacturing productivity.

    我們預期第三季毛利率介於71.9%至72.5%。第三季毛利率較第二季略為上升,因我們預期價格調升與製造生產力提升將帶來改善。

  • We expect Q3 operating expenses to be in the range of $305 million to $312 million. Our Q3 operating expenses are expected to be significantly higher sequentially as a result of the benefit of $51 million Straumann settlement in Q2, which reduced operating expenses. We are very pleased with the settlement and are putting the funds to work by stepping up our investment in consumer advertising with a brand-new campaign and stepping up our reach and coverage. The new ads focus on the significant technical and clinical advantages of our Invisalign system and differentiates our doctor-centered model for consumers. It will launch next week in North America and soon after in China. These ads will carry on throughout the second half of 2019.

    我們預期第三季營業費用將落在3.05億至3.12億美元之間。由於第二季認列5,100萬美元的Straumann和解利益、使營業費用下降,因此我們預期第三季營業費用在季比上將顯著提高。我們對這項和解非常滿意,並正將資金投入使用,透過全新活動加大消費者廣告投資,同時提升我們的觸及與覆蓋。新廣告聚焦於我們Invisalign系統顯著的技術與臨床優勢,並向消費者凸顯我們以醫師為中心的模式之差異化。該活動將於下週在北美推出,並於不久後在中國推出。這些廣告將在2019年下半年持續投放。

  • Q3 operating margin should be in the range of 19.8% to 20.5%. Our effective tax rate is expected to be approximately 24%. Diluted shares outstanding is expected to be approximately 80.6 million, exclusive of any share repurchases. Taken together, we expect our Q3 diluted earnings per share to be in the range of $1.09 to $1.16. In addition, we expect to repurchase at least $100 million of our stock in the open market in Q3. As we continue our operational expansion efforts, we expect capital expenditures for Q3 to be approximately $50 million to $55 million, and we expect depreciation and amortization to be $24 million to $26 million.

    第三季營業利益率應落在19.8%至20.5%之間。我們預期有效稅率約為24%。稀釋後流通在外股數預期約為8,060萬股,不包含任何庫藏股回購。綜合以上,我們預期第三季稀釋後每股盈餘將落在1.09至1.16美元之間。此外,我們預期第三季將在公開市場至少回購1億美元的本公司股票。隨著我們持續推動營運擴張,我們預期第三季資本支出約為5,000萬至5,500萬美元,折舊與攤銷預期為2,400萬至2,600萬美元。

  • Given our Q3 outlook, I want to make a few comments on the full year. Based on the current growth rates in our business to date and our planned investments for the remainder of the year, we now anticipate 2019 total revenue growth rate to be at the low end of our long-term operating model target of 20% to 30%. We also expect Invisalign revenue and volume growth to be at the low end of our long-term operating model target. We anticipate operating margin to be below the low end of our long-term model at approximately 22%, which reflect the impact from increased legal fees and the planned corporate structure reorganization as well as increased investment in consumer marketing, Invisalign store closure costs, partially offset by the benefit from the Straumann settlement.

    基於我們對第三季的展望,我想就全年補充幾點。依據截至目前的業務成長率以及我們對今年剩餘期間的投資規劃,我們現在預期2019年總營收成長率將位於我們長期營運模型目標20%至30%的低端。我們也預期Invisalign營收與出貨量成長將位於我們長期營運模型目標的低端。我們預期營業利益率將低於我們長期模型低端、約為22%,反映法律費用增加與規劃中的公司架構重組,以及加大消費者行銷投資、Invisalign門市關閉成本的影響;上述部分由Straumann和解利益所帶來的效益部分抵銷。

  • Now I'll turn the call back to Joe for closing comments.

    現在我把電話交回給Joe做結語。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, John, and thanks for joining our call today. Before we close, I want to comment on a few things that I think are important to remember, given our lower-than-expected Invisalign volumes this quarter and a more cautious outlook for China in Q3.

    謝謝你,John,也謝謝各位今天參與我們的電話會議。在結束之前,鑑於本季Invisalign出貨量低於預期,以及我們對第三季中國市場較為審慎的展望,我想就幾件我認為重要、值得記住的事情做些說明。

  • First, our fundamentals are squarely in place and our outlook for the remainder of the year is clearly within our long-term model, on top of a record 35% last year. We don't believe the second and third quarter in any way reflects our full potential.

    第一,我們的基本面穩固到位,而我們對今年剩餘期間的展望也明確落在我們的長期模型範圍內,且是在去年創下35%歷史新高的基礎之上。我們不認為第二季與第三季在任何方面反映了我們的全部潛力。

  • Our product technology, operational scale and consumer brand awareness are all significant advantages in a huge market that we're addressing with only 10% share today. The opportunity to bring better smiles to millions is not a zero-sum game. We're working hard to ensure that we continue to gain share. So while we acknowledge competition, we also embrace it because it drives our own innovation, which ultimately is great for millions of global patients who have yet to reap the benefits of this.

    我們的產品技術、營運規模以及消費者品牌知名度,都是我們在一個龐大市場中的重大優勢;而我們目前在該市場的市占率僅約10%。為數百萬人帶來更美好的笑容,並不是零和競爭。我們正努力確保能持續提升市占。因此,雖然我們承認競爭的存在,但我們也擁抱競爭,因為它推動我們自身的創新,而這最終將造福全球數以百萬計尚未享受到其效益的患者。

  • Finally, before I open the call for questions, I want to take a minute to congratulate Simon Beard, who has taken on a new role as Senior VP for the Americas. I also want to welcome Markus Sebastian to our executive management team as the new Senior VP of EMEA. As many of you know, Simon was responsible for the market development and operational execution of all products and services in EMEA region since 2014. Under Simon's leadership, the EMEA region has consistently grown more than 30% compounded annual growth rate with strong performance across the entire region and customer base. His knowledge of the market and ability to drive strategic programs and initiatives across the region have delivered exceptional results and make him an ideal leader for the Americas region.

    最後,在我開放提問之前,我想花一點時間恭喜Simon Beard,他已接任美洲區資深副總裁的新職務。我也要歡迎Markus Sebastian加入我們的高階管理團隊,擔任新的EMEA資深副總裁。如各位所知,自2014年以來,Simon一直負責EMEA地區所有產品與服務的市場開發與營運執行。在Simon的領導下,EMEA地區以超過30%的年複合成長率持續成長,並在整個區域與客戶基礎上展現強勁表現。他對市場的了解,以及推動區域內策略性計畫與倡議的能力,帶來了卓越成果,使他成為領導美洲區的理想人選。

  • Markus also joined Align a year ago and has been responsible for Align's core European commercial organization focused on the orthodontic channel. He's also served as the interim GM of Germany and France country markets. Markus is an experienced leader and General Manager with a proven track record in global commercial operations in sales, strategic marketing, product development and change management processes. His deep understanding of the health care markets in EMEA, Asia Pacific and the U.S. are an asset to Align. We're very glad to have Markus assume responsibility for the EMEA region.

    Markus也在一年前加入Align,並負責Align在歐洲以矯正通路為核心的商業組織。他也曾擔任德國與法國市場的代理總經理。Markus是一位資深領導者與總經理,在全球商業營運方面具備經驗,涵蓋銷售、策略行銷、產品開發以及變革管理流程,且有可驗證的績效。他對EMEA、亞太與美國醫療保健市場的深刻理解,對Align而言是一項資產。我們非常高興由Markus接任EMEA地區的職責。

  • With that, I want to thank you again for joining our call. I look forward to seeing many of you at upcoming financial conferences and meetings, including the Invisalign GP Summit in November in Las Vegas, where we'll host an analyst meeting. Stay tuned for more information. With that, I'll turn the call over to the operator for questions.

    最後,再次感謝各位參與我們的電話會議。我期待在即將到來的財務研討會與會議上見到各位,包括11月在拉斯維加斯舉行的Invisalign GP高峰會,屆時我們將舉辦分析師會議。請持續關注更多資訊。接下來我把電話交給接線員,開始提問。

  • Operator

    Operator

  • (Operator Instructions) Our first question comes from the line of Erin Wright from Crédit Suisse.

    (接線員指示)我們的第一個問題來自Crédit Suisse的Erin Wright。

  • Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

    Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

  • Can you parse out some of the components of the sequentially slower growth in Americas where maybe there were pockets of stronger growth that you could at least call out that were obviously offset by some of those competitive dynamics that you were speaking to? And how should we be thinking about the quarterly progression there? And also where are you seeing most of the competitions doing? Is it mostly DTC? Or is it some of component of the GP offerings as well? And how do you expect that to progress?

    你能否拆解一下美洲地區季比成長放緩的幾個構成因素?是否有一些成長較強的區塊至少可以點出來,而這些顯然被你先前提到的某些競爭動態所抵銷?我們應該如何看待那裡的季度走勢?另外,你看到競爭主要在做什麼?主要是DTC(直面消費者)嗎?還是也包含GP(一般牙醫)方案的一部分?你預期這會如何發展?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Erin, first of all, when you look at the Americas, this is split up because the Americas side includes Latin America and Brazil, which is growing over 100%. There's terrific growth down there. So our focus is mainly, when we talk about a little bit of a slowdown, has been in the North American marketplace, the U.S. and Canada.

    是的。Erin,首先,當你看美洲地區時,這裡面包含拉丁美洲與巴西,而那邊的成長超過100%。那裡的成長非常亮眼。因此,當我們談到些許放緩時,我們的重點主要是在北美市場,也就是美國與加拿大。

  • And when you talk about segments that have done well was what I read in my script too is when you look at teens or we call them tweens, between 7 and 10, they're up 140% year-on-year in the Americas. It's our fastest growing group and that reflects the technology we put in place around Invisalign First, which is made for dental expansion in that age of patient, and also our mandibular advancement product also that I think you know about, too. So that's been a terrific segment for us.

    至於表現良好的細分市場,正如我在講稿中提到的,當你看青少年或我們稱之為tweens(7到10歲)時,美洲地區年增達140%。這是我們成長最快的族群,反映了我們在Invisalign First周邊所導入的技術,該產品是為這個年齡層患者的齒弓擴張而設計;此外也包括我們的下顎前移產品,我想你也知道。因此,這對我們而言是一個非常出色的細分市場。

  • And our adult segment too has been strong. It's that 20- to 29-year-old that we saw some amount of slowdown over time. But when you get into the older classifications, we're still seeing really good strong growth in those areas. So yes, I feel well that our portfolio that I talked about in my script, which is iGo and also our Lite product, can address that segment of 20 to 29 that we think is looking for a price point and also some convenience that we're sure that we can offer through our ortho channels and also our GP channels, too.

    我們的成人族群也表現強勁。我們看到隨時間推移,20到29歲這個年齡層出現一定程度的放緩。但當你進入更高年齡層的分類時,我們仍在那些領域看到非常良好且強勁的成長。所以是的,我對我在講稿中提到的產品組合感到有信心,包括iGo以及我們的Lite產品,能夠切入我們認為正在尋找價格帶與便利性的20到29歲族群;我們確信可透過矯正通路以及GP通路提供這些。

  • On the competition in general is how I framed your second part of your question. When you think about DTC versus I would interpret that as just standard competition, it's really hard to say exactly how to break this up. But in general, we feel that when you look at that specific consumer segment, it's more of a DTC segment. It's not necessarily a traditional segment that they would be appealing to.

    關於整體競爭,我是用這個角度來回應你問題的第二部分。當你想到 DTC 相對於——我會把那解讀為一般性的競爭——其實很難精確地說要怎麼切分。但整體而言,我們認為當你看那個特定的消費者族群時,它更偏向 DTC 的族群。它不一定是他們會去吸引的傳統族群。

  • So in general, I feel good about our positioning. I think our position with orthos and GPs continues to be strong. I mean look at our most -- it was great to be in the field. We were in Asia last week. We were also in North America that I mentioned the previous week, and we've been involved with a lot of customers and just what I said in my script. I mean there's -- we know that things are being trialed out there from a consumer standpoint. We feel so good about the feedback we get about the clinical capabilities of Invisalign, the consistency of it, its interaction with iTero, which is it's really unmatched in the marketplace, and then all of them reaching out to say how they want to compete against that DTC segment, and we're the only company that can really join hands with them and help them compete in that area.

    所以整體而言,我對我們的定位感到很有信心。我認為我們在矯正科醫師與一般牙醫(GP)那邊的地位仍然很強。我的意思是,看看我們最近——能到第一線真的很棒。我們上週在亞洲。前一週我也提到我們在北美,而且我們和很多客戶有深入互動,也就是我在講稿裡說的那些。我的意思是——我們知道從消費者角度來看,外面確實有一些東西正在試行。我們對於 Invisalign 的臨床能力、其一致性、以及它與 iTero 的互動所得到的回饋感到非常好——這在市場上確實是無可匹敵的——而且大家都主動來找我們,說他們想要對抗那個 DTC 族群,而我們是唯一一家真正能與他們攜手、幫助他們在那個領域競爭的公司。

  • Operator

    Operator

  • Our next question comes from the line of Jon Block from Stifel.

    我們的下一個問題來自 Stifel 的 Jon Block。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • I'm going to try to ask 2 and I'll ask them one at a time. So the first, long-term guidance is 20% to 30% rev guide, but the guidance for next quarter is 17% at the midpoint. It looks like high teens, Joe, for the back half of '19. I know you had some commentary, but I guess the real question is, 1 or 2 quarters don't make a trend, but how do we foot sort of that high teens to each year-over-year growth guide versus the long term of 20% to 30%? And what would drive the reacceleration? And then I'll ask, hopefully, a tighter follow-up.

    我會試著問兩個問題,並且一次問一個。第一個,長期指引是營收成長 20% 到 30%,但下季的指引在中位數是 17%。看起來 2019 年下半年是高十幾%,Joe。我知道你有一些評論,但我想真正的問題是,雖然 1、2 個季度不構成趨勢,但我們要如何把這種每年年增高十幾%的成長指引,和長期 20% 到 30% 的目標對接起來?而什麼會驅動成長再加速?然後我再問一個,希望更精準的追問。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, Jon. General, from a teens standpoint, you know what our product portfolio is and how well it competes in that sense. When we talk about this slowdown right now, part of it is -- a huge part of it is China. And China obviously is a big teen season as we roll into China now. And we're confident we'll be able to perform in that marketplace too, Jon, and there's still demand there. There's just -- after what we saw in the second quarter, we have some basic uncertainty there and that's reflected in what our guidance is. But it certainly doesn't decrease our confidence in the sense of our portfolio, our positioning and the movements that we're making in the Tier 3 and Tier 4 cities that I mentioned in my script. It's a really important part of us expanding in that geography and just giving us more mass in the sense of being exposed to broader patients across that area. So overall, I feel good about that.

    是的,Jon。整體來說,從十幾%的角度,你也知道我們的產品組合是什麼,以及它在競爭上的表現。當我們談到目前這個放緩時,其中一部分——很大一部分——是中國。而中國顯然是一個很大的「十幾%」因素,因為我們現在正逐步深入中國市場。我們也有信心能在那個市場表現良好,Jon,那裡仍然有需求。只是——在我們看到第二季的情況之後,我們對那裡有一些基本的不確定性,這也反映在我們的指引之中。但這當然不會降低我們對產品組合、定位,以及我在講稿裡提到我們在三線與四線城市所採取行動的信心。那是我們在該地理區域擴張非常重要的一環,也讓我們在接觸那個區域更廣泛的患者方面,能有更大的量體。所以整體而言,我對此感覺良好。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Okay. And then just the follow-up there, can you just expand a little bit on the competitive dynamics? You said things seem to work itself out in early 3Q, so what was that, Joe? Was that commentary specific more to the traditional ortho channel where there might've been some trialing and then they said, "Hey, we don't have a comparable product." Or maybe you can just split what those comments were specific to?

    好的。那接著追問一下,你能不能再多談一點競爭動態?你說在第三季初似乎就自行消化了,所以那是什麼情況,Joe?那段評論是否更偏向傳統矯正通路——可能有人試用後說:「嘿,我們沒有可比的產品。」——或者你可以把那些評論具體是針對哪一塊拆開說明?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, they're specific to North America in the ortho channel that you mentioned, Jon. And we see in the first basic 24 days in July, we're seeing a significant uptick in that part of the marketplace. So we say work that out. It just seems that we've had doctors tell us they've tried these products, they haven't been satisfied with the software or the results that it had, the data, whatever. And then we see an inflection point from a growth standpoint as we move into July. That's significant.

    嗯,那是針對你提到的北美矯正通路,Jon。而我們看到 7 月前 24 天的初步數據,在那一塊市場出現了顯著回升。所以我們說它「自行消化」。看起來就是有醫師告訴我們,他們試過那些產品,但對其軟體或結果、資料等等並不滿意。然後當我們進入 7 月時,從成長角度看到一個轉折點。這很顯著。

  • Secondly is when we look at Asia and the July orders also including China, we've seen an uptick in China also. So just in general, I'm talking about -- we're talking about as a team is, from a volume standpoint, we've seen an increase in that sense, it gives us confidence that those things are working themselves out.

    第二點是,當我們看亞洲市場以及 7 月的訂單(也包含中國)時,我們也看到中國有回升。所以整體而言,我們團隊在談的是:從量的角度來看,我們看到有所增加,這讓我們更有信心,覺得那些事情正在自行消化、回到正軌。

  • Operator

    Operator

  • Our next question comes from the line of Glen Santangelo from Guggenheim Securities.

    我們的下一個問題來自 Guggenheim Securities 的 Glen Santangelo。

  • Glen Joseph Santangelo - Analyst

    Glen Joseph Santangelo - Analyst

  • Joe, I just want to talk to you about, clearly, the competitive landscape seems like it's getting worse, but yet you raised your prices on July 1. I mean are you seeing any price sensitivity in the market? And then when you think about the competitive landscape, put the DTC channel beside for a second, but when you think about the traditional players that are also now selling into the GP and the ortho market, are you seeing any sort of price sensitivity from your customer base at all?

    Joe,我想跟你談談:很明顯競爭環境看起來在惡化,但你們卻在 7 月 1 日調漲了價格。我的意思是,你們在市場上有看到任何價格敏感度嗎?另外,當你思考競爭環境時,先把 DTC 通路放一邊,但就那些也開始賣進 GP 與矯正市場的傳統玩家而言,你們在客戶群中有看到任何價格敏感度嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Glen, it's hard to say, our market has always been price sensitive. And when you look at our portfolio in the sense of how we put things together with our comprehensive product and then our Lite products, products like E5 and E7 and the iGo that I talked about too these have all been positioned to hit a certain price point, not just for doctors but for doctors with their patients, too. When you talk about competition and increasing whatever, again, it's out there, the traditional players that we know about. I'll talk about the DTC channel in a second. But in general, what we find is there's no scale yet, there's no scale in the software side, there's no scale in the supply side. There's a ways to go, there's no challenge in the teen segment at all, it's primarily simple cases on the adult side. And so it's not that we don't take it seriously. It's just that we feel that we have a really strong sales force. The iTero integration with our product line is so strong in that way, it makes it easier for doctors to work with us and to work with patients also. Our operations are unmatched in the sense of now we produce 0.5 million to 600,000 aligners a day. It's not easy to do those things.

    Glen,很難說,我們的市場一直都對價格敏感。而當你看我們的產品組合——我們如何把全方位(comprehensive)產品與 Lite 產品搭配起來——像我也提到的 E5、E7 以及 iGo,這些都被定位在某個價格帶,不只是對醫師而言,也包括醫師面對患者時的價格帶。談到競爭以及各種增加的情況,再次強調,市場上確實有我們所知道的傳統玩家。我等一下也會談 DTC 通路。但整體而言,我們發現他們還沒有規模——軟體端沒有規模、供應端也沒有規模。還有一段路要走;在青少年(teen)族群上完全沒有挑戰,主要是在成人端的簡單病例。所以並不是我們不認真看待。只是我們認為我們有非常強的銷售團隊。iTero 與我們產品線的整合在這方面非常強,讓醫師更容易與我們合作,也更容易與患者合作。就營運而言,我們的能力無可匹敵——現在我們每天生產 50 萬到 60 萬副隱形牙套。要做到那些並不容易。

  • So overall, is the landscape changing? Sure it is. I mean our key patents ran off at the end of 2017, as you know. We're in the 2019 and we're seeing competition slowly ramp up, but we're not saying that it's been material this quarter, we're just recognizing that it's been out there.

    所以整體而言,競爭環境有在改變嗎?當然有。我的意思是,如你所知,我們的關鍵專利在 2017 年底到期。我們現在在 2019 年,看到競爭正逐步升溫,但我們並不是說這一季已經造成重大影響,我們只是承認競爭確實存在。

  • On the DTC's channel price, again, I'll go back to our portfolio. The products like Lite, products like iGo, our simpler products like E7 specifically, those are designed for simple cases. Basically, that's what DTC does. They do Social 6, lower crowding, things that are orthodontically simple. These products have been aligned for that, too. Our job is to get those products in our doctor's hands and to get in front of the patients and show them what an opportunity it is to work with a doctor and its product line to give them the kind of outcomes that they expect. And also they give them a chance to be able to work with a doctor hand-in-hand. If they don't like the treatment at some point in time, they can continue to progress with that doctor to make it better, too.

    關於 DTC 通路的價格,我再回到我們的產品組合來談。像 Lite、像 iGo,以及我們更簡單的產品,特別是 E7,這些都是為了簡單案例而設計的。基本上,這就是 DTC 在做的事。他們做的是 Social 6、較低擁擠度等在齒顎矯正上相對簡單的案例。這些產品也都已針對那類需求做了對齊。我們的工作是把這些產品交到醫師手上,並走到病患面前,讓他們看到:與醫師及其產品線合作,能帶來他們所期待的那種治療結果,是一個很好的機會。同時也讓他們有機會能與醫師手把手、密切合作。如果他們在某個時間點不喜歡治療進展,也可以繼續與那位醫師一起調整,讓它變得更好。

  • Glen Joseph Santangelo - Analyst

    Glen Joseph Santangelo - Analyst

  • I appreciate those comments. Anything regarding ASP's slight downtick sequentially? Was it mix? Was it discounting? Anything you can add on that front?

    我很感謝這些評論。關於 ASP 連續期略微下滑,有什麼可以補充的嗎?是產品組合(mix)的影響嗎?是折扣(discounting)嗎?在這方面你還能補充些什麼?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Primarily, it was exchange, and that's what we're leaning into. John, you can...

    主要是匯率因素,而這也是我們目前著力的重點。John,你可以……

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I mean it's -- like you said, Glen, it's down about $15. $10 of that was exchange and then the rest of it was mix. So nothing material from the previous quarter.

    是的。我的意思是——就像你說的,Glen,大約下降了 15 美元。其中 10 美元是匯率,剩下的則是產品組合(mix)。所以相較上一季沒有任何重大的變化。

  • Operator

    Operator

  • Our next question comes from the line of Brandon Couillard from Jefferies.

    我們的下一個問題來自 Jefferies 的 Brandon Couillard。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Joe, just starting in the Americas region. Why do you think the DTC channel is having a negative impact now? You kind of talk about it perhaps having a positive halo effect. And then can you speak to the productivity of the 100 new reps that you've hired and whether or not those are ramping in line with your expectations or not?

    Joe,先從美洲地區談起。你認為為什麼 DTC 通路現在會帶來負面影響?你有提到它可能帶來正向的光環效應。另外,你能談談你們新聘的 100 位業務代表的生產力,以及他們的上手速度是否符合你們的預期嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Brandon, first of all, on the DTC piece is, look, I think it's -- there's light and dark in that, right? I do feel that SmileDirectClub and Candid, they've raised the category of awareness significantly and we hear throughout our doctor base whether the orthodontic side or GP side, the patients come in asking about clear aligners much more than they have before, so it forces that conversation, it gives them an opportunity to engage at a level that I feel with just our advertising alone, it would have never gotten to that level. So that's the positive side.

    是的。Brandon,首先談 DTC 這塊:你看,我覺得這件事有光明面也有陰暗面,對吧?我確實認為 SmileDirectClub 和 Candid 大幅提升了市場對這個品類的認知;我們也從醫師客群那邊聽到,不論是矯正科或一般牙科(GP),病患進來詢問透明牙套的頻率比以前高很多,因此迫使這個對話發生,讓他們有機會以我認為僅靠我們的廣告不可能達到的程度去互動。這就是正面的一面。

  • The negative side is it's -- there are some price competition. That segment offers $2,000 or less kind of a case for a simple case and it's pushed some of the doctor office models and it's pushed our portfolio, too. And what we're saying is that we've always known there's a 10% overlap. And educating our customers, having customers be able -- which is our doctors, having those customers be able to use an iTero scanner to help to communicate and visualize exactly the treatment plan would be, getting patients some offering up in the sense that they have issues during the treatment time that they can be addressed by a doctor directly, all those things are things that we just have to make sure we take better advantage of with our doctors and the channels that we work with in order to take advantage of that increased interest that we see out there.

    負面的一面是——確實存在一些價格競爭。那個區隔對於簡單案例提供 2,000 美元或更低的方案,這對部分牙醫診所的商業模式造成壓力,也對我們的產品組合造成壓力。而我們要說的是,我們一直都知道大約有 10% 的重疊。教育我們的客戶,讓客戶——也就是我們的醫師——能夠使用 iTero 掃描儀來協助溝通並視覺化具體的治療計畫;並在提供病患方案時強調:若治療期間出現問題,可以由醫師直接處理;所有這些都是我們必須確保能與醫師及我們合作的通路更好地加以運用的事情,才能把握我們在市場上看到的那股更高的興趣。

  • From a new rep standpoint, the second part of your question, Brandon, we put roughly 100 in North America last year. We watch these statistics, I do, really closely, and it's amazing to watch the productivity, what happens. It's almost like clockwork. It takes 9 months, we're certain, before they're really up to speed and you can see the productivity versus what our normal territory managers would have. And as we move into the third quarter right now, I'm looking at those statistics, we see their almost, we call it breadth and reach, and the number of accounts that they're calling on and the depth of those accounts are almost equal today. So as we go into the second half of this year, we're really confident about higher productivity with these reps. And you combine that with our new consumer ad campaign and the breadth of that consumer ad campaign that John talked about, we think, will help to drive that demand, and with the concierge service increase also which is significant, will allow us to be able to take advantage of that demand in a way we really couldn't in the past without -- with those resources.

    至於新業務代表,也就是你問題的第二部分,Brandon,我們去年在北美大約新增了 100 位。我們會非常密切地追蹤這些統計數據,我自己也是,真的很密切,而觀察生產力的變化非常有意思。幾乎就像按表操課一樣。我們很確定需要 9 個月,他們才會真正上手,你也能看到他們的生產力相對於我們一般的區域經理會是什麼樣子。而當我們現在進入第三季,我在看這些數據時,他們的——我們稱之為覆蓋廣度與觸及(breadth and reach)——以及他們拜訪的帳戶數量與對這些帳戶的深度,今天幾乎已經相當。所以進入今年下半年,我們對這些業務代表更高的生產力非常有信心。再加上我們新的消費者廣告活動,以及 John 提到的該活動的覆蓋廣度,我們認為將有助於帶動需求;同時禮賓式服務(concierge service)的提升也很顯著,將使我們能以過去在缺乏這些資源時做不到的方式來把握這些需求。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Okay. And for the follow-up, John, could you help us reconcile some of the components of the higher OpEx outlook or the reduced operating margin outlook for the second half? And is the legal and corporate reorganization spend still 150 to 200 basis points in terms of headwind for the year now? And is there any reason that, that extends perhaps into 2020?

    好的。追問一下,John,你能否協助我們釐清下半年較高的 OpEx 展望或較低的營業利益率展望的幾個組成因素?另外,法律與公司重組支出就今年而言,是否仍是 150 到 200 個基點的逆風?以及是否有任何原因會讓這項影響延伸到 2020 年?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • No, Brandon. It's the 1.5 to 2 points of expenses that's for the full year for that legal and reorganization, and we don't expect that to continue into next year.

    不會,Brandon。法律與重組相關的 1.5 到 2 個百分點費用是針對全年而言,我們不預期會延續到明年。

  • Operator

    Operator

  • Our next question comes from the line of Ravi Misra from Barrington Capital (sic) [Berenberg Capital].

    我們的下一個問題來自 Barrington Capital(原文如此)[Berenberg Capital] 的 Ravi Misra。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • Just 2 quick ones on (inaudible). Number one, I think you had said on the last call the gross margin profile at the end of the year you'd still be kind of towards the low end of that 73% to 78% range. Is that still the case? And then secondly, just a little bit more detail if I may ask for on the dynamics in your North American business. Just curious, are you seeing the detailing more on your lower volume GPs or orthos? Or who is really feeling the most competitive pressure in terms of your customer base?

    關於(聽不清)我有兩個很快的問題。第一,我記得你在上次電話會議提到,年底的毛利率走勢仍會偏向 73% 到 78% 區間的低端。現在仍是如此嗎?第二,如果可以的話,想請你更詳細說明北美業務的動態。我很好奇,你們看到的下滑(detailing)更多是出現在低量的一般牙科(GP)或矯正科(ortho)客戶嗎?或就你們的客戶基礎而言,究竟是哪些客戶感受到最強的競爭壓力?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • So on your first question, Ravi, on the gross margin improvement, we still expect to see sequential improvement. So we've guided up from Q2 for gross margin in the third quarter, and we expect that improvement to continue into the fourth quarter.

    針對你的第一個問題,Ravi,關於毛利率改善,我們仍預期會看到逐季改善。因此我們已在第三季將毛利率指引自第二季上調,而我們也預期這項改善會延續到第四季。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Ravi, it's Joe. Your second question is the dynamics of that. It's a really good question. When we look at that on the GP side, I mean it's hitting us both on the orthos and the GP side. Our orthodontic data for the second quarter indicated that there was really a reduction in number of adults that were going through orthodontists, and we know we recognize that. On the GP side, it hits the GP side also but what we see with our DSOs specifically is they're up significantly in growth. I mean they have been focused on Invisalign and hit it harder. So within that segment as GP, I think the individual practice was hit a little bit harder. The DSOs have really grabbed products like iGo, institute that in your organization, done much better with it.

    Ravi,我是 Joe。你第二個問題是關於這些動態。這是個非常好的問題。我們來看一般牙科(GP)這邊的情況,我的意思是,矯正科與一般牙科兩邊都受到影響。我們第二季的矯正科數據顯示,透過矯正專科醫師進行治療的成人數量確實有所下降,我們知道也承認這點。在一般牙科端也受到影響,但我們看到特別是 DSO(牙科服務組織)成長顯著上升。我的意思是,他們一直把重點放在 Invisalign,並且更積極推進。所以在 GP 這個區隔內,我認為個別診所受到的衝擊稍微更大一些。DSO 則確實抓住了像 iGo 這類產品,把它導入組織內,表現好得多。

  • Operator

    Operator

  • Our next question comes from Elizabeth Anderson.

    我們的下一個問題來自 Elizabeth Anderson。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • Can you...

    你能不能……

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Elizabeth, can you -- like, we can barely hear you.

    Elizabeth,你可以——呃,我們幾乎聽不到你的聲音。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • Oh, sorry about that. Can you hear me better now?

    喔,不好意思。你現在聽得比較清楚嗎?

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Oh, that's better.

    喔,這樣好多了。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • We got it now, yes.

    我們現在收到了,是的。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • Okay. Perfect. Sorry about that. So just in terms of mix in between your comprehensive and noncomprehensive products, can you talk about if there were certain like areas, in particular, the noncomprehensive products, where you saw like a shift between the first and second quarters?

    好的。完美。不好意思。那就你們的全方位(comprehensive)與非全方位(noncomprehensive)產品之間的組合來看,你能談談是否有某些領域——特別是非全方位產品——在第一季與第二季之間出現了某種轉移嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Elizabeth, when you look at that, our comprehensive held in there really well. You remember -- it's really important to remember that comprehensive, our larger sized docs, like Diamond, Diamond Plus, Platinum, rely almost exclusively on those product lines because the discount that we give them really makes it easier for them to be able to move up and down the portfolio. They like that product line on the comprehensive side only because you get the 5-year additional aligners. So when you move to the noncomp and that increase, our Lite product lines stood out really well. Our E7 did extremely well. And also iGo by far was a real winner in that piece. So just remember, a product like iGo too has one individual additional aligners that's offered with it, too. So for those kind of simple cases, that also gives the doctors confidence to be able to attack those things with more of a middle-range kind of a product.

    Elizabeth,從這點來看,我們的全方位產品表現其實相當穩健。你要記得——非常重要的是要記得,全方位產品、我們較大規模的醫師客戶(例如 Diamond、Diamond Plus、Platinum)幾乎完全依賴這些產品線,因為我們給他們的折扣,讓他們在產品組合中上下調整更容易。他們偏好全方位端的那條產品線,主要是因為你可以獲得額外 5 年的追加牙套(aligners)。所以當你轉到非全方位、且那邊出現成長時,我們的 Lite 產品線表現非常突出。我們的 E7 表現非常好。另外 iGo 在那一塊更是明顯的贏家。所以請記得,像 iGo 這樣的產品也同樣提供 1 次個別的追加牙套。因此對於那種較簡單的病例,這也讓醫師更有信心,用更偏中階的產品去處理這些案例。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • That makes sense. And then from an R&D perspective, I know you sort of over time have had like a steady drip of new products like mandibular advancement or Invisalign First. Is there anything you could sort of talk about that you guys are working on in terms of further clinical advancements?

    了解。接著從研發角度來看,我知道你們長期以來持續推出新產品,例如下顎前移(mandibular advancement)或 Invisalign First。在進一步的臨床進展方面,有沒有什麼你們正在進行、可以談一談的?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • We'd have to kill you, Elizabeth, if we told you that. It's top secret, okay? It's no mystery that we've been working on what's called a rapid palate expander. So when we talk about Invisalign First, you think about that's a dental arch expansion product, so you take your teeth that are in your arch and you basically expand those teeth. A palate expander actually takes -- from a morphological standpoint, it just widens your mouth completely. That is something we've been working on. I feel we have a good line of sight on how to get that done. But it'll be several more quarters before we introduce anything like that.

    Elizabeth,如果我們告訴你,就得把你「滅口」了。這是最高機密,好嗎?不過也不是秘密,我們一直在做一個叫做快速腭擴弓器(rapid palate expander)的東西。所以當我們談 Invisalign First,你可以把它想成是牙弓擴張產品,也就是把牙弓裡的牙齒基本上往外擴。而腭擴弓器則是——從形態學角度——會把你的口腔整體寬度直接擴大。這是我們一直在研發的項目。我覺得我們對如何把它做出來已經有很清晰的方向。但在我們推出這類產品之前,還需要再過好幾個季度。

  • Operator

    Operator

  • Our next question comes from the line of John Kreger from William Blair.

    我們的下一個問題來自 William Blair 的 John Kreger。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • Joe, can you just expand a little bit more on what you're seeing in China? If you're willing, how much is it slowing? Are you seeing any signs of market maturation? And are there any competitive pressures that you're seeing there? Or are you seeing it just in terms of a little bit more reticence on the part of the consumer to spend?

    Joe,你能不能再多談一點你們在中國看到的情況?如果你願意的話,放緩的幅度有多大?你們是否看到任何市場成熟的跡象?以及你們在那邊是否看到任何競爭壓力?或者你們看到的只是消費者在支出上更為保守一些?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • John, I'd start with the end of your question. It's a little more reticence on consumers to spend. I mean you're seeing that on other consumer channels when you look at what's going on, particularly with some U.S.-based companies and obviously the issues that we have between the United States and China right now. As far as the competition goes, John, I'd say Angel Align is a very competent competitor in China from an overall standpoint, but it's not that we feel that there's been any dramatic change in a sense of their competitive positioning or their ability to do certain cases or others. But I mean we recognize them as a competent competitor. It's just when you look at the different cities too, Tier 3, Tier 4, there's a huge GP area in the Tier 3 and Tier 4 city. That's why we put iGo and the GP sales force to go into it. The Tier 1 cities are more orthodontic. And so we do segment in that way.

    John,我先從你問題的最後一段開始。確實是消費者在支出上更為保守一些。我的意思是,當你看目前的情況,尤其是一些以美國為基地的公司,以及顯然目前美中之間的問題,你在其他消費通路也看得到這種現象。至於競爭方面,John,我會說 Angel Align 在中國整體而言是一個非常有實力的競爭對手,但我們並不覺得他們的競爭定位或處理某些病例的能力等方面,有出現任何戲劇性的變化。不過我們確實把他們視為有實力的競爭者。另外你也要看不同城市:三線、四線城市有很大的全科牙醫(GP)市場。這也是為什麼我們推出 iGo,並配置 GP 銷售團隊去切入。一線城市則更偏正畸。所以我們會用這種方式做市場分眾。

  • When you talk about maturation or some kind of saturation, we just don't feel that. Again, we're moving into the teen season in China, and the third quarter is normally their biggest quarter. Obviously, there's still a lot of spending that goes on in China around the teen side. And so no, I honestly feel that this is consumer sentiment in general. It's reflected in other consumer-based businesses. It's not, to your point, broadly driven by competition or by any kind of, I'd say, saturation of clear aligners in that marketplace. I think we still have a long way to go before we'd ever reach that point.

    至於你提到的成熟或某種飽和,我們並不這麼認為。再說一次,我們正進入中國的青少年旺季,而第三季通常是他們最大的一季。顯然在中國,青少年端仍有大量支出。所以不,我老實說我認為這是整體消費者情緒。這也反映在其他以消費者為主的產業。並不是如你所說,主要由競爭或任何我會稱之為透明牙套在該市場的飽和所驅動。我認為距離真正到達那個點,我們還有很長的路要走。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • Great. And maybe one quick follow-up for this young adult demographic that you've been talking about. What other levers do you have to really kind of improving the convenience that they perceive with Invisalign versus other options beyond sort of that classic price trade-off?

    很好。再追問一個關於你一直在談的年輕成人族群。除了傳統的價格取捨之外,為了提升他們對 Invisalign 相較其他選項的便利性認知,你們還有哪些槓桿可以運用?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, with, I'd say, young adults is it's how many doctor visits that they have to make, John, and there are some technologies I don't want to get into right now but they're more remote technologies that would allow a doctor to see these patients less frequently from an office standpoint and be able to monitor their progress remotely. And I think those kinds of things, they hit the convenience side, but it also hits the cost side because the less time they spend in an office, there's less doctor time associated with it so it's lower cost, too. So there is a convenience and a price point we think the technology and doctor understanding of specific kind of products and when and where to use them will allow us to be able to get at that segment better.

    嗯,我會說,對年輕成人而言,關鍵在於他們需要回診的次數有多少,John;而且有一些技術我現在不想深入談,但它們屬於更偏遠端的技術,能讓醫師在診所端不必那麼頻繁地見到這些患者,並能遠端監測他們的進度。我認為這類做法一方面打到便利性,但也會影響成本端,因為他們在診所花的時間越少,所需的醫師時間就越少,因此成本也更低。所以我們認為,在便利性與價格點上,透過技術,以及醫師對特定產品、以及何時何地使用它們的理解,將使我們能更好地切入那個族群。

  • Operator

    Operator

  • Our next question comes from the line of Steve Beuchaw from Wolfe Research.

    我們的下一個問題來自 Wolfe Research 的 Steve Beuchaw。

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • First, just one more clarification on China. Embedded in the outlook for the back half, am I hearing you right that you assume China actually gets worse? And then I know John Kreger asked this, but could you put any numbers around China in 2Q and what you're assuming for the balance of the year?

    首先,再釐清一下中國。在你們對下半年展望的假設中,我是否理解正確:你們假設中國其實會變得更糟?另外我知道 John Kreger 也問過,但你能否提供一些數字,說明中國在第二季的情況,以及你們對今年剩餘期間的假設?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, Steve, this is John. We assume China kind of stays as we've seen. So we saw some of that slowdown in the second half of the quarter -- second quarter, and we assume that, that continues not knowing how that consumer sentiment is going to change over the next few months.

    是的,Steve,我是 John。我們假設中國大致維持在我們目前看到的狀態。所以我們在第二季後半段——第二季——看到一些放緩,我們假設這種情況會延續,因為我們也不知道未來幾個月消費者情緒會如何變化。

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • Okay. And then the e-mail that I'm getting most frequently here is how are they thinking now about the LRP, the 20% to 30% growth range beyond the next couple quarters? And what are the drivers there? Joe, I appreciate that you called out that the competitive trialing might fade in China we all would imagine gets better. Is that the whole story? We feel good about the LRP because of those 2 things?

    好的。接著我這邊最常收到的 e-mail 是:他們現在如何看待 LRP(長期計畫),也就是未來幾個季度之後 20% 到 30% 的成長區間?其驅動因素是什麼?Joe,我很感謝你提到在中國的競爭性試用可能會消退,而我們也都會想像中國會好轉。這就是全部的故事嗎?我們對 LRP 有信心,是因為這兩件事嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, we're sticking with 20% to 30% with confidence, Steve. There is nothing that really changed in that sense. And John, you'd...

    是的,Steve,我們有信心維持在 20% 到 30%。在這方面其實沒有任何真正的改變。而 John,你會...

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • That's how we're allocating resources and investing for that long-term growth model of revenue 20% to 30%. We're making investments where they're appropriate and looking for return on those investments to work with our long-term growth model.

    這就是我們如何配置資源並投資,以支撐營收 20% 到 30% 的長期成長模型。我們在適當之處進行投資,並尋求這些投資的回報,以配合我們的長期成長模型。

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • So does that mean the...

    所以這是否意味著...

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, Steve, I'll just reemphasize, China is not going away, right? I mean it's a big market. It's a phenomenon. The other part that I think we talked about is not -- we just got back. We were in Asia last week. It's not necessarily apparent as -- the rest of them -- when you look at APAC, it's so strong. You have Japan approaching 50% growth rates or more. You have -- it's an incredibly strong region overall. We think that we'll get through this China situation. It's going to continue to be our second-biggest market place. And I feel really good about our investments over there too because I think it addresses this consumer sentiment piece that we can be more like a Chinese company than be viewed as just an American company.

    是的,Steve,我再強調一次,中國不會消失,對吧?我的意思是,那是一個很大的市場。那是一種現象。我認為我們談到的另一部分是——不是——我們才剛回來。我們上週在亞洲。當你看亞太地區(APAC)時,它非常強勁,這點未必那麼明顯——其他地區——。你看到日本接近 50% 或更高的成長率。整體而言,這是一個極其強勁的區域。我們認為我們會度過這個中國的情況。它將持續是我們第二大的市場。而且我對我們在那邊的投資也感覺非常好,因為我認為這能回應消費者情緒這一塊,讓我們更像一家中國公司,而不是被視為只是一家美國公司。

  • Operator

    Operator

  • Our next question comes from the line of Jeff Johnson from Baird.

    我們的下一個問題來自 Baird 的 Jeff Johnson。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Guys, can you hear me okay?

    各位,聽得到我嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes.

    聽得到。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • John, I wanted to go back to Brandon's question just on margins. Obviously, you reiterated 150 to 200 basis point impact from the legal and the reorg and what have you for the year. But the rest of the takedown kind of in the second half guidance from a margin perspective ended up around 20% or so is that just the increased spend to try to reinvigorate top line? Or what other kind of levers get you to that 20% operating margin instead of kind of the mid-20s we were thinking?

    John,我想回到 Brandon 關於利潤率的問題。顯然,你重申今年法律費用、重組等因素會帶來 150 到 200 個基點的影響。但從利潤率角度來看,下半年指引其餘的下修,最後大概落在 20% 左右,這只是因為增加支出以試圖重新帶動營收成長嗎?或者還有什麼其他槓桿,會讓你們的營業利益率到 20%,而不是我們原本以為的 20% 中段(mid-20s)?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, that gets us lower, Brandon -- or Jeff, from the investments that we're making in marketing. So we're making those media investments in the third quarter. We expect that to continue into the fourth quarter, and that's a reflection in the overall op margin rate that I gave. All right.

    是的,Brandon——或 Jeff——這會讓我們更低,主要是因為我們在行銷上的投資。所以我們在第三季會進行那些媒體投資。我們預期第四季也會持續,這也反映在我給出的整體營業利益率水準上。好。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Fair enough. And Joe, maybe just a question on ClinCheck and kind of your confidence that those software glitches, issues, whatever the saving issues were, all of that rolled into one, confidence that you're past that, number one. And then maybe talk about your employee base in Costa Rica. Obviously, you've had a couple of competitors go down there and open treatment planning facilities in pretty close locations. Was that impacting in the second quarter at all? Does that impact over the short term going forward? Just how to think about that.

    了解。另外 Joe,想請教一下 ClinCheck,以及你對那些軟體故障、問題——不管是什麼儲存問題——總之全部合在一起,你對已經度過那段狀況的信心,第一點。第二點也請談談你們在哥斯大黎加的員工基礎。顯然,你們有幾個競爭對手到那邊,在相當接近的地點開設治療規劃中心。這在第二季有造成任何影響嗎?短期內接下來會有影響嗎?我們該如何看待這件事?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes Jeff, on the software release we had, I mean it was unfortunate. But we -- it's contained, and we know exactly what happened, and that's been cleaned up broadly across the world. On the -- when you think about Costa Rica too, we've had a lot of pressure on that organization. It's not necessarily because competitors have move down there and we have lost some employees to them. It's just been our capacity. We've had -- our growth has been phenomenal. You still look at these stock rates. They're huge. It takes us -- I think I've mentioned before, Jeff, it takes us about 6 months to add capacity, basically, people, technicians to Costa Rica to really get them up to speed where they can deal with customers. And we are a little bit behind the curve on that, and customers felt it. The software that we released that you referenced put pressure on them because then we had to go back and redo some cases, and that obviously put pressure on them and put pressure across our whole customer base when we did that. But it has nothing to do with -- SDC obviously has treatment planning down there, and some of our more traditional competitors have moved people down there, but we haven't had an attrition rate that's significantly different in that area than what we've had before.

    是的 Jeff,關於我們那次軟體版本釋出,我的意思是,確實很不幸。但我們——已經把它控制住了,我們也完全知道發生了什麼,而且已在全球範圍內廣泛清理修正。至於——當你想到哥斯大黎加時,我們那個組織也承受了很大壓力。這不一定是因為競爭對手搬到那邊,而我們把一些員工流失給他們。主要只是我們的產能問題。我們的成長非常驚人。你仍然看看這些病例量(stock rates)。它們非常龐大。Jeff,我想我之前提過,我們大約需要 6 個月才能在哥斯大黎加增加產能,基本上就是增加人力、技術人員,並真正讓他們上手到能夠面對客戶。而我們在這方面有點落後於需求曲線,客戶也感受到了。你提到的那次軟體釋出也對他們造成壓力,因為我們必須回頭重做一些案例,這顯然對他們造成壓力,也在我們這麼做時對整個客戶群造成壓力。但這與——SDC 顯然在那邊有治療規劃,以及我們一些較傳統的競爭對手把人員移到那邊——無關;我們在那個地區的離職率並沒有顯著不同於以往。

  • So we've added capacity there. We're going to add more capacity in the second half of this year so that we can take care of some of the increases in volume we see at times because if you -- when you do see these increases in volume, it's not like they go away in 2 weeks. They ripple through this organization for 30 or 40 days. And we need to be able to have some little extra capacity to allow us to be able to address that.

    所以我們已經在那邊增加了產能。今年下半年我們還會再增加更多產能,以便在某些時候能應對我們看到的量能增加,因為如果你——當你看到這些量能增加時,它不會在兩週內就消失。它會在這個組織裡連鎖影響 30 到 40 天。而我們需要能有一些額外的緩衝產能,讓我們可以處理這些情況。

  • Operator

    Operator

  • Our next question comes from the line of Matthew O'Brien from Piper Jaffray.

    我們的下一個問題來自 Piper Jaffray 的 Matthew O'Brien。

  • Matthew Oliver O'Brien - MD and Senior Research Analyst

    Matthew Oliver O'Brien - MD and Senior Research Analyst

  • Joe, as I think about the quarter and the outlook for the business, I continually hear that Align has better products from clinicians. That's clear. It's just it seems like in the marketplace, that message isn't being heard. So I'm wondering what you can do to turn things around there. And I know there's some of these investments, but can you be more specific on how you turn things around in North America somewhat quickly with these investments? And the same goes for China where it's a consumer product, it's not a medically necessary product, versus us encountering kind of a slow bleed as you have more competition in both geographies over the next several years.

    Joe,當我思考本季以及業務展望時,我一直聽到臨床醫師認為 Align 的產品更好。這很明確。只是看起來在市場上,這個訊息沒有被聽見。所以我想知道你們能做些什麼來扭轉這種情況。我知道你們會做一些投資,但你能否更具體說明,如何透過這些投資在北美相對快速地扭轉局面?中國也是同樣的問題,因為這是消費性產品,不是醫療必需品;相較之下,我們是否會在未來幾年於兩個地區面臨更多競爭而出現某種緩慢流失?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Matthew, I'm not sure how to talk about the competition part more than what I have so far, right? We -- I think we've categorize them well. We know what their capabilities are. It's somewhat limited. When you say how to get at that, when some of these cases are offered for free or they're offered for $800 or $750, some orthos are going to try it. I mean if I was an ortho, I'd try it too given where we've been in the marketplace and where our prices are or whatever. And so I think that's just part of the competitive environment or whatever. But what we're being very clear about, we don't see a systemic loss to our traditional competitors in any way. So I don't want to infer that at all either.

    Matthew,關於競爭那一塊,我不確定還能比我目前說的再多談些什麼,對吧?我們——我認為我們已經把他們分類得很清楚。我們知道他們的能力是什麼。相對有限。你說要怎麼應對,當有些案例是免費提供,或是以 800 美元或 750 美元提供時,有些矯正醫師會去試試看。我的意思是,如果我是矯正醫師,考量我們在市場上的位置以及我們的價格等等,我也會去試。所以我認為那就是競爭環境的一部分之類的。但我們非常清楚的是,我們並沒有看到在任何方面對我們傳統競爭對手的系統性流失。所以我也不想做任何那樣的暗示。

  • From a China standpoint, look, China, again, I think we talked about that in a few other calls, a few seconds ago, China will continue to be strong. Consumer sentiment there is consumer sentiment. We're going to continue to invest there. We're going to put more salespeople in place. We'll follow through with our -- continuing our training centers. Our manufacturing centers all are put in place, and we expect that China will continue to grow and be for the foreseeable future the second-largest area that we sell to. John, any...

    從中國的角度來看,聽著,中國——再一次,我想我們在其他幾次電話會議、就在剛剛幾秒前也談過——中國將會持續強勁。那裡的消費者情緒就是消費者情緒。我們會持續在那裡投資。我們會配置更多業務人員。我們會持續推進——持續擴展我們的培訓中心。我們的製造中心都已就位,我們預期在可預見的未來,中國將持續成長,並且仍會是我們銷售的第二大區域。John,還有...

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Sorry. No, go ahead.

    抱歉。不,請繼續。

  • Matthew Oliver O'Brien - MD and Senior Research Analyst

    Matthew Oliver O'Brien - MD and Senior Research Analyst

  • Okay. And then everybody's focusing on the negatives here, and there's -- I get that. But there was some positives in the quarter I'd love to hear a little bit more about. You'd started touching on it a bit, but the iTero number, and I know there was some seasonality to it, was just phenomenal again. Some of that's DSO-related. I'd love to hear a little bit more about outside the DSOs what was driving that and when we expect to see a lot more of that volume from all the iTero placements. And same thing goes to doc training. I think those are some of the best numbers that we've seen in a while. When some of that training may manifest into higher volumes for the entire organization.

    好的。然後大家都把焦點放在這裡的負面因素上,而且——我理解。但本季其實也有一些正面表現,我很想多聽你們談一點。你剛剛有稍微提到,但 iTero 的數字——我知道有一些季節性因素——再次表現得非常驚人。其中一部分與 DSO 有關。我想多了解一下,除了 DSO 之外,還有哪些因素在推動這個表現,以及我們預期何時能從所有 iTero 裝機中看到更多的量能。同樣也想問醫師訓練(doc training)。我認為那是我們一段時間以來看到最好的數字之一。這些訓練何時可能轉化為整個組織更高的量能。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Matt, we appreciate a positive comment like that because there were a lot of good things this quarter. One thing you missed is, you look at EMEA up 39% and the consistency of the growth across that EMEA region has really been amazing in that sense. I mentioned the other parts of APAC too is this strong growth that we saw, and again, we verified that last week when we were over to see the team. And then the North America side, I mean when you look at these tweens, 7 to 10, up 140%, and some of our other age groups, they have been very -- extremely strong. DSO marketplace has been great for us, and GP is still growing double digits and is not taken for granted in this business because we've had some terrible -- if you go back years ago, of GP growth that were sub-double digits. We're continuing to do well in that segment.

    Matt,我們很感謝你這樣的正面評論,因為本季確實有很多好消息。你漏提了一點:你看 EMEA 成長 39%,而且整個 EMEA 區域的成長一致性在這方面真的非常驚人。我也提到 APAC 其他地區的強勁成長,而且我們上週去看團隊時也再次驗證了這點。再來北美方面,我是說,當你看這些青少年(tweens,7 到 10 歲)成長 140%,以及我們其他一些年齡層,也都非常——極其強勁。DSO 市場對我們來說表現很棒,而 GP 仍維持雙位數成長,在這個產業裡這並不是理所當然,因為如果你回頭看幾年前,GP 的成長曾經很糟——低於雙位數。我們在這個區隔持續表現良好。

  • But you pointed to iTero specifically, and I mean that was really an amazing quarter for iTero. So you have world-leading technology in iTero. And with our 5D launch, it wasn't available in the United States. It's not yet -- we're still working through the FDA. But in other parts of the world, it has been made available. We're seeing both orthos and dental -- dentists or general practitioners are really interested in that product line, too. We have good sales force combined with our iTero sales force that's direct but also with our Invisalign sales force, too.

    但你特別提到 iTero,我的意思是,iTero 這一季真的非常出色。所以 iTero 擁有全球領先的技術。而在我們推出 5D 之後,它在美國尚未上市。目前還沒有——我們仍在走 FDA 的流程。但在世界其他地區,已經可以供應。我們看到無論是矯正科(orthos)或牙科——牙醫或一般牙科醫師(general practitioners)也都對這條產品線非常有興趣。我們有很好的銷售團隊,結合我們 iTero 的直銷團隊,也同時結合我們 Invisalign 的銷售團隊。

  • And more and more as -- it's no secret that dental is going digital. To start the whole digital piece, the front end of it is the scanner. Having the kind of technology we have with iTero, you could see in some of the statistics that I mentioned in my opening, 13.7 million scans done. I think 3.8 million that were done for restorative scans, meaning they had really nothing to do for the most part with Invisalign, and that sense kind of shows you the versatility of that product line, too. So those areas are very -- they're very strong in the area.

    而且越來越——這不是秘密,牙科正在走向數位化。要啟動整個數位化流程,前端就是掃描器。以我們 iTero 的技術水準,你可以從我在開場提到的一些統計數據看到:已完成 1,370 萬次掃描。我想其中有 380 萬次是用於修復(restorative)掃描,意思是大多數情況下與 Invisalign 幾乎無關,而這也在某種程度上顯示了這條產品線的多功能性。所以這些領域都非常——在這方面非常強勁。

  • You talked about doc training. We did have some terrific numbers across all geographies for the quarter. That's always a strong leading indicator of docs' interest in future Invisalign cases. It breaks down differently by different regions on how fast they'll go. But as an overall signal in the sense of what's in front of us in the interest from a doctor standpoint, the doctor training thing is good, and I'm glad you picked up on it.

    你提到醫師訓練(doc training)。本季我們在所有地理區域都有一些非常亮眼的數字。那一直是醫師對未來 Invisalign 病例興趣的一個強力領先指標。不同地區的轉化速度會有所不同。但作為整體訊號,從醫師端的興趣來看,醫師訓練這件事是好的,我也很高興你注意到了。

  • Operator

    Operator

  • Our next question comes from line of Steven Valiquette from Barclays.

    我們的下一個問題來自 Barclays 的 Steven Valiquette。

  • Steven James Valiquette - Research Analyst

    Steven James Valiquette - Research Analyst

  • So not to get too granular in what transpired over the past 3, 4 months, but just coming back to the June quarter case volume for a moment, I guess when you guys provided guidance for 2Q obviously that was in late April. Then you guys were at a lot of conferences through mid-June with the message that everything seemed okay. I guess I'm just wondering if most of these negative pressure points hit you maybe late in the quarter and in the month of June in particular. And when we come back to your comment that in North America, you're seeing improving trends in the first few weeks of Q3, are you just comparing July to June in particular? Just curious to kind of getting a little more color of how things kind of transpired throughout the quarter as we think about some of these pros and cons in that result.

    我不想把過去 3、4 個月發生的事講得太細,但回到 6 月這一季的病例量(case volume)來看,我想你們在提供 2Q 指引時顯然是在 4 月下旬。接著你們在 6 月中旬之前參加了很多會議,傳達的訊息是看起來一切都還好。我想知道的是,這些負面壓力點是否大多是在本季後段、尤其是 6 月才開始衝擊你們。另外回到你們提到北美在 3Q 前幾週看到改善趨勢的評論,你們是特別拿 7 月去跟 6 月比嗎?只是想多了解一下,本季期間事情大致是如何演變的,因為我們在評估這個結果的一些利弊。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Steve, like you said, not to be over granular though, I think China by far was one where -- when you got to June and all, it was more difficult than what we had anticipated. Our China team is terrific too, so you do count on these guys to be able to deliver toward the end of the quarter. And we see that time and time again. It just didn't materialize, and that consumer sentiment piece became more and more visible to us as we got through the quarter in that way.

    Steve,如你所說,不要講得太細,不過我認為中國無疑是其中一個——到了 6 月等時點,情況比我們原先預期更困難。我們的中國團隊也非常出色,所以你確實會期待這些夥伴能在季末交出成果。而且我們一次又一次看到這種情況。但這次沒有實現,且隨著季度推進,消費者信心那一塊對我們來說變得越來越明顯。

  • And North America, I'd say, in general, we are good with the team volume. It's up 24%, same as what we had in the previous quarter, up 24%, too. So there wasn't really a teen issue from a North America standpoint, but we did see some slowdown as we went into the quarter, also. As you think about July in general when we talk about that increase, we're not just comparing it to June, we're talking about the entire quarter, the first quarter -- the first and second quarters are what we look at when we talk about that increase or else we wouldn't mention it.

    至於北美,我會說整體而言,我們對青少年(teen)量能是滿意的。成長 24%,跟上一季一樣也是成長 24%。所以從北美角度來看,並沒有真正的青少年問題,但我們在進入本季時也確實看到一些放緩。當我們談到 7 月整體的增加時,我們不只是拿它跟 6 月比,我們是看整個季度——我們看的是第一季與第二季,當我們談到那個增加時就是以此為基準,否則我們不會提。

  • Operator

    Operator

  • Our next question comes from the line of Michael Ryskin from Bank of America Merrill Lynch.

    我們的下一個問題來自美國銀行美林(Bank of America Merrill Lynch)的 Michael Ryskin。

  • Michael Leonidovich Ryskin - Associate

    Michael Leonidovich Ryskin - Associate

  • A quick one on the following quarter and then one just to follow up again on something that Steve just touched on with the last one. For starters, for 3Q, if you just sort of look at your commentary in international, sequentially down with the China pressures, and you look at U.S., North America, even if you account for the 2% impact you had on 3Q last year, it seems like it's a pretty aggressive cut to the North America outlook. So I was just wondering how much conservative is [built] to that, especially since your point on improving trends in the first part of July? I guess I'm saying is, was it really kitchen-sink guide? Or sort of what's your outlook there?

    先快速問一個關於下一季的問題,然後再追問一個剛才 Steve 在上一題提到的點。首先,對於 3Q,如果你看你們對國際市場的評論,因中國壓力而呈現季比下滑;再看美國、北美,即便你把去年 3Q 的 2% 影響納入考量,看起來對北美展望的下修幅度仍相當激進。所以我想問,這裡面有多少是保守因素(conservative)[納入],尤其是你們提到 7 月前段有改善趨勢?我的意思是,這是不是所謂的「把所有壞消息一次反映」(kitchen-sink)式指引?或者你們的展望到底是什麼?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Mike, this is John. Really, there's no change in how we guide. We look at a lot of factors and understanding of the market being a few weeks into the quarter so we're -- no change in terms of how we guide. We're just trying to put the pieces that we see. And as we mentioned with 2Q, we had some slowdown primarily China, in June. And we want to be reflective of what we see. So no change in how we guide. We give our best estimate at a point in time, and that's what we've done.

    Mike,我是 John。其實,我們的指引方式沒有改變。我們會看很多因素,並在進入季度幾週後對市場有更多理解,所以——在指引方式上沒有任何改變。我們只是試著把我們看到的各個拼圖拼起來。而且如同我們在 2Q 提到的,我們在 6 月主要因中國而出現一些放緩。我們希望能反映我們所看到的情況。所以指引方式沒有改變。我們在某個時間點給出我們最好的估計,而我們就是這麼做的。

  • Michael Leonidovich Ryskin - Associate

    Michael Leonidovich Ryskin - Associate

  • All right. I appreciate that. And quick follow-up, again, just going through the sort of the bridge in 2Q, if you look at where international came in versus expectations, it may have been a little bit light, but it feels like the majority of the delta was actually in North America and especially on your comments on just June softness in China. We know roughly how big your China business is for you so it shouldn't have been that meaningful an impact, especially it was only 1-month dynamic. So is there anything going on outside of China? I mean is there anything that you can comment on in terms of your local presence there? You've got the manufacturing site built out. You got some of your other facilities that you're establishing there. Any other dynamics in play besides just the June consumer sentiment?

    好的。感謝你。再快速追問一下,同樣是看 2Q 的那個調節橋(bridge),如果你看國際業務相較於預期的表現,可能稍微偏弱一點,但感覺差異(delta)的大部分其實是在北美,尤其是你提到中國 6 月的疲軟。我們大概知道你們在中國的業務規模,所以影響應該不至於那麼大,尤其這只是 1 個月的動態。所以中國以外還有什麼狀況嗎?我是說,就你們在當地的布局,有沒有什麼可以評論的?你們已經把製造基地建好了。你們也在那邊建立其他一些設施。除了 6 月消費者信心之外,還有其他因素在發酵嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Nothing that we saw out of the ordinary, Mike. It was -- we looked at the demand that we saw, some of the pressure that we saw in June. But it was around the consumer sentiment, like Joe said, that China team delivers quarter after quarter. So we have felt very confident that we've got a great business there in terms of the investments that we've made in treatment planning and now manufacturing and training centers and so on. So we'll continue to invest and grow. Just calling a number that we see.

    Mike,我們沒有看到任何異常。我們檢視了所看到的需求,以及 6 月看到的一些壓力。但就像 Joe 說的,那主要是消費者信心的問題;中國團隊一季又一季都能交出成績。因此,對於我們在那裡的業務,我們一直非常有信心,因為我們已在治療規劃、現在的製造,以及訓練中心等方面做了投資。所以我們會持續投資並成長。只是把我們看到的數字如實說明。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Thanks, Mike.

    謝謝你,Mike。

  • Operator

    Operator

  • Our next question comes from the line of Nathan Rich from Goldman Sachs.

    下一個問題來自高盛(Goldman Sachs)的 Nathan Rich。

  • Nathan Allen Rich - Research Analyst

    Nathan Allen Rich - Research Analyst

  • John, I actually just had a question on the ASP outlook and how we should be thinking about that sequentially. And as you look going forward, do you have any change in kind of promotional activity or discounts kind of baked into how you're thinking about where ASPs trend from here?

    John,我其實想問一下 ASP 的展望,以及我們應該如何看待其環比走勢。另外,往前看,你們在對 ASP 走勢的判斷中,是否有納入任何促銷活動或折扣力度的變化?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, Nate. When we think about ASPs and, really, what we saw at the end of -- and we guided for at the end of last year was essentially flat ASPs. We have puts and takes, as you know, with our business between international growth and comprehensive versus noncomprehensive. But what we've seen through this year and our Q3 guide is consistent to the fact that, notwithstanding FX, we expect it to be about flat as we go through. So we have puts and takes to it, but from an overall ASP, that is flat.

    好的,Nate。談到 ASP,基本上我們在去年底所看到的情況,以及我們當時給出的指引,是 ASP 大致持平。如你所知,我們的業務在國際成長,以及綜合(comprehensive)與非綜合(noncomprehensive)之間,會有一些此消彼長的因素。但今年以來我們看到的情況,以及我們對 Q3 的指引,都一致顯示:撇除匯率(FX)因素,我們預期 ASP 在接下來仍大致持平。所以雖然有一些拉鋸因素,但整體 ASP 就是持平。

  • And the promotions that we have like we have every quarter, no difference in terms of how we're thinking. We're trying to drive increased utilization, trying to drive growth in our business, and promotions continue as usual.

    至於促銷,我們每一季都有,對我們的思考方式沒有差別。我們希望提升使用率、推動業務成長,促銷會照常進行。

  • Nathan Allen Rich - Research Analyst

    Nathan Allen Rich - Research Analyst

  • Okay. I appreciate that. And then just with the case guidance for 3Q, is it possible to just kind of give us a sense in terms of orders of magnitude in the step-down in the growth rate? How much was from the slowdown that you saw in China versus maybe a more competitive environment in North America just as we think about the relative impact of those factors?

    好的。感謝說明。另外,關於 3Q 的病例數(case)指引,能否請你大概量化一下成長率下滑的幅度?就相對影響而言,其中有多少來自你們在中國看到的放緩, versus 可能是北美競爭環境更激烈?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, Nate, most of what we saw, that slowdown or the guidance that we gave, was related to China. Like you said, we saw this in June. And that's a reflection of how we've guided. So the majority of that was related to China.

    好的,Nate,我們看到的大部分放緩,或我們給出的那個指引,主要都與中國有關。如你所說,我們在 6 月看到了這個情況。而這也反映在我們的指引方式上。所以其中大多數都與中國相關。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Thank you, everyone, for joining us. This concludes our conference call today. If you have further questions, please contact myself or Madelyn Homick in Investor Relations. Thanks, and have a great day.

    感謝各位加入我們。今天的電話會議到此結束。如有進一步問題,請聯絡我或投資人關係部的 Madelyn Homick。謝謝,祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.

    今天的會議到此結束,您現在可以掛斷電話線。感謝您的參與。